{"title_page": "Frozen Crown", "text_new": "{{Infobox musical artist\n| name             = Frozen Crown\n| Img              = \n| caption          = \n| landscape        = yes\n| background       = group_or_bandhei\n| origin           = [[Milan]]\n| genre            = {{flatlist|\n*[[Power metal]]\n*[[Heavy metal music|Heavy metal]]\n}}\n| years_active     = 2017\u2013present\n| label            = [[Scarlet Records]]\n| website          = {{URL|scarletrecords.it/artists/frozen-crown}}\n| current_members  = Giada \"Jade\" Etro<br/>Federico Mondelli<br/>Talia Bellazecca<br/>Filippo Zavattari<br/>Alberto Mezzanotte<br/>\n}}\n\n'''Frozen Crown''' is an Italian [[power metal]] band formed 2017 in [[Milan]], [[Lombardy]]. In 2018, the band released its debut album, ''The Fallen King'', which garnered large media exposure. Four tracks from the album were also released as singles, notably ''Kings'', which surpassed one million views on YouYube. The band's second album, ''Crowned In Frost'', was released in 2019.<ref>{{Cite web|url=https://scarletrecords.it/artists/frozen-crown/|title=FROZEN CROWN \u2013 SCARLET RECORDS \u2013 OFFICIAL SITE|language=en-US|access-date=2020-04-16}}</ref><ref>{{Cite web|url=https://www.spirit-of-metal.com/en/band/Frozen_Crown|title=Frozen Crown - discography, line-up, biography, interviews, photos|website=www.spirit-of-metal.com|access-date=2020-04-16}}</ref> In the following year three of the album's tracks were made into videos, with ''Neverending'' reaching almost five million views.<ref>{{Cite web|url=https://www.youtube.com/watch?v=9o0imRANjm0|title=FROZEN CROWN - Neverending (Official Video)|last=|first=|date=12 March 2019|website=YouTube|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n\n==References==\n\n{{Reflist}}\n\n[[Category:Italian power metal musical groups]]\n[[Category:Italian heavy metal musical groups]]\n[[Category:Scarlet Records artists]]\n[[Category:Musical groups established in 2017]]\n", "text_old": "{{Infobox musical artist\n| name             = Frozen Crown\n| Img              = \n| caption          = \n| landscape        = yes\n| background       = group_or_bandhei\n| origin           = [[Milan]]\n| genre            = {{flatlist|\n*[[Power metal]]\n*[[Heavy metal music|Heavy metal]]\n}}\n| years_active     = 2017\u2013present\n| label            = [[Scarlet Records]]\n| website          = {{URL|scarletrecords.it/artists/frozen-crown}}\n| current_members  = Giada \"Jade\" Etro<br/>Federico Mondelli<br/>Talia Bellazecca<br/>Filippo Zavattari<br/>Alberto Mezzanotte<br/>\n}}\n\n'''Frozen Crown''' is an Italian [[power metal]] band formed 2017 in [[Milan]], [[Lombardy]]. In 2018, the band released its debut album, ''The Fallen King'', which garnered large media exposure. Four tracks from the album were also released as singles, notably ''Kings'', which surpassed one million views on YouYube. The band's second album, ''Crowned In Frost'', was released in 2019.<ref>{{Cite web|url=https://scarletrecords.it/artists/frozen-crown/|title=FROZEN CROWN \u2013 SCARLET RECORDS \u2013 OFFICIAL SITE|language=en-US|access-date=2020-04-16}}</ref><ref>{{Cite web|url=https://www.spirit-of-metal.com/en/band/Frozen_Crown|title=Frozen Crown - discography, line-up, biography, interviews, photos|website=www.spirit-of-metal.com|access-date=2020-04-16}}</ref> In the following year three of the album's tracks were made into videos, with ''Neverending'' reaching almost five million views.<ref>{{Cite web|url=https://www.youtube.com/watch?v=9o0imRANjm0|title=FROZEN CROWN - Neverending (Official Video)|last=|first=|date=12 March 2019|website=YouTube|url-status=live|archive-url=|archive-date=|access-date=}}</ref>\n[[Category:Italian power metal musical groups]]\n[[Category:Italian heavy metal musical groups]]\n[[Category:Scarlet Records artists]]\n[[Category:Musical groups established in 2017]]\n", "name_user": "Laanders", "label": "safe", "comment": "Ref list", "url_page": "//en.wikipedia.org/wiki/Frozen_Crown"}
{"title_page": "Lakdar Boussaha", "text_new": "{{short description|French-Algerian footballer|bot=PearBOT 5}}\n{{Infobox football biography\n| name     = Lakdar Boussaha\n| image    = FBBP01 - FCN - 20151028 - Coupe de la Ligue - Lakdar Boussaha.jpg\n| fullname = Lakdar Boussaha\n| birth_date  = {{Birth date and age|1987|7|18}}\n| birth_place = [[Bourg St Maurice]], France\n| height   = 1.75 m\n| position = [[Forward (association football)|Forward]]\n| currentclub = [[\u00c9toile Carouge FC|\u00c9toile Carouge]]\n| clubnumber  = 9\n| youthyears1 = {{0|0000}}\u20132008\n| youthclubs1 = US Annecy Le Vieux\n| youthyears2 = 2008\u20132009\n| youthclubs2 = [[US Boulogne|Boulogne]]\n| years1 = 2009\u20132010 \n| clubs1 = [[US Boulogne|Boulogne]] \n| caps1  = 2\n| goals1 = 0\n| years2 = 2010\u20132012\n| caps2  = 51\n| clubs2 = [[Besan\u00e7on RC|Besan\u00e7on]]\n| goals2 = 20\n| years3 = 2012\u20132013\n| caps3  = 17\n| clubs3 = [[JSM B\u00e9ja\u00efa]]\n| goals3 = 2\n| years4 = 2013\u20132017\n| clubs4 = [[FC Bourg-P\u00e9ronnas|Bourg-P\u00e9ronnas]]\n| caps4  = 114\n| goals4 = 38\n| years5 = 2017\u20132019\n| clubs5 = [[Grenoble Foot 38|Grenoble]]\n| caps5  = 23\n| goals5 = 1\n| years6 = 2019\u2013\n| clubs6 = [[\u00c9toile Carouge FC|\u00c9toile Carouge]]\n| caps6  = 14\n| goals6 = 8\n| club-update = 14:42, 25 November 2019 (UTC)\n}}\n'''Lakdar Boussaha''' (born July 18, 1987) is a French-Algerian professional [[Association football|footballer]] who plays as a [[Forward (association football)|forward]] for [[\u00c9toile Carouge FC]].<ref>{{Cite news|url=https://www.lequipe.fr/Football/FootballFicheJoueur34206.html|title=Lakhdar BOUSSAHA - Football : la fiche de Lakhdar BOUSSAHA (Grenoble)|work=L'Equipe.fr|access-date=2018-02-07|language=fr}}</ref><ref>{{cite web |url=http://www.dzfoot.com/joueur.php?joueur_id=1941&saison_id=15 |title=Archived copy |accessdate=2009-10-05 |url-status=dead |archiveurl=https://web.archive.org/web/20091005084252/http://www.dzfoot.com/joueur.php?joueur_id=1941&saison_id=15 |archivedate=2009-10-05 }}</ref>\n\n==Club career==\nBorn in [[Bourg St Maurice]], France, Boussaha started his career in the junior ranks of ''US Annecy Le Vieux''. At the start of the 2008\u201309 season, he joined the [[US Boulogne]] reserve team, scoring 15 league goals and adding 7 more in the cup. He was promoted to the first team at the start of the 2009\u201310 season, and after netting 11 goals in 5 games for the reserve team, he was given his [[Ligue 1]] debut on October 4, 2009, in a league game against [[Lille OSC]].<ref>http://www.lavoixdessports.com/USBCO/2009/10/04/article_et-si-c-etait-l-heure-de-lakhdar-boussah.shtml</ref> Boussaha started the game and was replaced at the 54th minute.<ref>http://www.lfp.fr/ligue1/feuilleMatch.asp?saison=2009/2010&code_evt=D1&code_jr_tr=J08&num_ordre=1 {{webarchive|url=https://web.archive.org/web/20091007023049/http://www.lfp.fr/ligue1/feuilleMatch.asp?saison=2009%2F2010&code_evt=D1&num_ordre=1&code_jr_tr=J08 |date=2009-10-07 }}</ref>\n\nAt the end of the 2009\u201310 season, the club announced that his contract would not renewed.<ref>[http://www.rmc.fr/editorial/111356/pas-d-offre-pour-thil-selon-wattez/ Pas d\u2019offre pour Thil selon Wattez]</ref>\n\nOn May 20, 2010, Boussaha went on trial with Algerian club [[JSM B\u00e9ja\u00efa]].<ref>[https://www.scribd.com/doc/33542696/C20-05-2010 BOUSSAHA LAKDAR, un autre \u00e9migr\u00e9 arrive]</ref>\n\nIn August 2019, Boussaha joined [[Swiss Promotion League]] club [[\u00c9toile Carouge FC]].<ref>[http://www.grenoblefoot.info/exgf38-lakdar-boussaha-rebondit-a-letoile-de-carouge-d3-suisse/ exGF38 \u2013 Lakdar Boussaha rebondit \u00e0 l\u2019\u00c9toile de Carouge (D3 Suisse)], grenoblefoot.info, 12 August 2019</ref>\n\n==References==\n{{Reflist}}\n\n{{DEFAULTSORT:Boussaha, Lakdar}}\n[[Category:1987 births]]\n[[Category:Living people]]\n[[Category:French people of Algerian descent]]\n[[Category:People from Albertville]]\n[[Category:Sportspeople from Savoie]]\n[[Category:Association football forwards]]\n[[Category:Algerian footballers]]\n[[Category:French footballers]]\n[[Category:US Boulogne players]]\n[[Category:Racing Besan\u00e7on players]]\n[[Category:JSM B\u00e9ja\u00efa players]]\n[[Category:Football Bourg-en-Bresse P\u00e9ronnas 01 players]]\n[[Category:Grenoble Foot 38 players]]\n[[Category:\u00c9toile Carouge FC players]]\n[[Category:Championnat National players]]\n[[Category:Championnat National 2 players]]\n[[Category:Ligue 1 players]]\n[[Category:Algerian Ligue Professionnelle 1 players]]\n[[Category:Swiss Promotion League players]]\n[[Category:Expatriate footballers in Switzerland]]\n", "text_old": "{{short description|French-Algerian footballer|bot=PearBOT 5}}\n{{Infobox football biography\n| name     = Lakdar Boussaha\n| image    = FBBP01 - FCN - 20151028 - Coupe de la Ligue - Lakdar Boussaha.jpg\n| fullname = Lakdar Boussaha\n| birth_date  = {{Birth date and age|1987|7|18}}\n| birth_place = [[Bourg St Maurice]], France\n| height   = {{height|m=1.75}}\n| position = [[Forward (association football)|Forward]]\n| currentclub = [[\u00c9toile Carouge FC|\u00c9toile Carouge]]\n| clubnumber  = 9\n| youthyears1 = {{0|0000}}\u20132008\n| youthclubs1 = US Annecy Le Vieux\n| youthyears2 = 2008\u20132009\n| youthclubs2 = [[US Boulogne|Boulogne]]\n| years1 = 2009\u20132010 \n| clubs1 = [[US Boulogne|Boulogne]] \n| caps1  = 2  \n| goals1 = 0\n| years2 = 2010\u20132012\n| caps2  = 51\n| clubs2 = [[Besan\u00e7on RC|Besan\u00e7on]]\n| goals2 = 20\n| years3 = 2012\u20132013\n| caps3  = 17\n| clubs3 = [[JSM B\u00e9ja\u00efa]]\n| goals3 = 2\n| years4 = 2013\u20132017\n| clubs4 = [[FC Bourg-P\u00e9ronnas|Bourg-P\u00e9ronnas]]\n| caps4  = 114\n| goals4 = 38\n| years5 = 2017\u20132019\n| clubs5 = [[Grenoble Foot 38|Grenoble]]\n| caps5  = 23\n| goals5 = 1\n| years6 = 2019\u2013\n| clubs6 = [[\u00c9toile Carouge FC|\u00c9toile Carouge]]\n| caps6  = 14\n| goals6 = 8\n| club-update = 14:42, 25 November 2019 (UTC)\n}}\n'''Lakdar Boussaha''' (born July 18, 1987) is a French-Algerian [[Association football|footballer]] who plays as a [[Forward (association football)|forward]] for [[\u00c9toile Carouge FC]].<ref>{{Cite news|url=https://www.lequipe.fr/Football/FootballFicheJoueur34206.html|title=Lakhdar BOUSSAHA - Football : la fiche de Lakhdar BOUSSAHA (Grenoble)|work=L'Equipe.fr|access-date=2018-02-07|language=fr}}</ref><ref>{{cite web |url=http://www.dzfoot.com/joueur.php?joueur_id=1941&saison_id=15 |title=Archived copy |accessdate=2009-10-05 |url-status=dead |archiveurl=https://web.archive.org/web/20091005084252/http://www.dzfoot.com/joueur.php?joueur_id=1941&saison_id=15 |archivedate=2009-10-05 }}</ref>\n\n==Club career==\nBorn in [[Bourg St Maurice]], France, Boussaha started his career in the junior ranks of ''US Annecy Le Vieux''. At the start of the 2008\u20132009 season, he joined the [[US Boulogne]] reserve team, scoring 15 league goals and adding 7 more in the cup. He was promoted to the first team at the start of the 2009\u20132010 season, and after netting 11 goals in 5 games for the reserve team, he was given his [[Ligue 1]] debut on October 4, 2009, in a league game against [[Lille OSC]].<ref>http://www.lavoixdessports.com/USBCO/2009/10/04/article_et-si-c-etait-l-heure-de-lakhdar-boussah.shtml</ref> Boussaha started the game and was replaced at the 54th minute.<ref>http://www.lfp.fr/ligue1/feuilleMatch.asp?saison=2009/2010&code_evt=D1&code_jr_tr=J08&num_ordre=1 {{webarchive|url=https://web.archive.org/web/20091007023049/http://www.lfp.fr/ligue1/feuilleMatch.asp?saison=2009%2F2010&code_evt=D1&num_ordre=1&code_jr_tr=J08 |date=2009-10-07 }}</ref>\n\nAt the end of the 2009\u20132010 season, the club announced that his contract would not renewed.<ref>[http://www.rmc.fr/editorial/111356/pas-d-offre-pour-thil-selon-wattez/ Pas d\u2019offre pour Thil selon Wattez]</ref>\n\nOn May 20, 2010, Boussaha went on trial with [[Algeria]]n club [[JSM B\u00e9ja\u00efa]].<ref>[https://www.scribd.com/doc/33542696/C20-05-2010 BOUSSAHA LAKDAR, un autre \u00e9migr\u00e9 arrive]</ref>\n\nIn August 2019, Boussaha joined [[Swiss Promotion League]] club [[\u00c9toile Carouge FC]].<ref>[http://www.grenoblefoot.info/exgf38-lakdar-boussaha-rebondit-a-letoile-de-carouge-d3-suisse/ exGF38 \u2013 Lakdar Boussaha rebondit \u00e0 l\u2019\u00c9toile de Carouge (D3 Suisse)], grenoblefoot.info, 12 August 2019</ref>\n\n==References==\n{{Reflist}}\n\n{{DEFAULTSORT:Boussaha, Lakdar}}\n[[Category:1987 births]]\n[[Category:Living people]]\n[[Category:French people of Algerian descent]]\n[[Category:People from Albertville]]\n[[Category:Association football forwards]]\n[[Category:Algerian footballers]]\n[[Category:French footballers]]\n[[Category:US Boulogne players]]\n[[Category:Racing Besan\u00e7on players]]\n[[Category:JSM B\u00e9ja\u00efa players]]\n[[Category:Football Bourg-en-Bresse P\u00e9ronnas 01 players]]\n[[Category:Grenoble Foot 38 players]]\n[[Category:\u00c9toile Carouge FC players]]\n[[Category:Championnat National players]]\n[[Category:Championnat National 2 players]]\n[[Category:Ligue 1 players]]\n[[Category:Algerian Ligue Professionnelle 1 players]]\n[[Category:Swiss Promotion League players]]\n[[Category:Sportspeople from Savoie]]\n[[Category:Expatriate footballers in Switzerland]]\n", "name_user": "Robby.is.on", "label": "safe", "comment": "Minor corrections.", "url_page": "//en.wikipedia.org/wiki/Lakdar_Boussaha"}
{"title_page": "Henri Termeer", "text_new": "{{multiple issues|\n{{cleanup reorganize|date=May 2017}}\n{{update|date=May 2017}}\n{{like resume|date=May 2017}}\n{{lead too long|date=May 2017}}\n{{overly detailed|date=September 2015}}\n}}\n{{Infobox person\n|image        = Henri Termeer 2012 BIO Convention.jpg\n|image_size   =\n|alt          = \n|caption      = Termeer 2012\n|birth_date   = {{Birth date|1946|2|28|df=y}}<ref name=\"Biotech_History\" />\n|birth_place  = [[Tilburg]], [[Netherlands]]<ref name=\"Biotech_History\" />\n| death_date = {{Death date and age|2017|05|12|1946|02|28|df=y}}\n| death_place = [[Marblehead, Massachusetts]], U.S.\n|alma_mater   = [[Erasmus University]]\n|occupation   = Executive <br> [[Biotechnology]] entrepreneur\n|years_active = \n|net_worth    = \n|boards       = Verastem<br>[[Genzyme]] (1983\u20132011)<br>Federal Reserve Bank of Boston<br>[[Abiomed|ABIOMED Inc]]<br>Massachusetts Institute of Technology Corporation<br>[[Massachusetts General Hospital]]<br>[[Partners HealthCare|Partners HealthCare System]]<ref name=\"Verastem_2015\">{{citation |url=http://www.verastem.com/about/directors.aspx |work=Verastem | year=2015 |accessdate=9 July 2015 |title=Board of Directors}}</ref><ref name=\"partners\">{{citation |url=https://www.partners.org/About/Company-Information/Leadership/Board-of-Directors.aspx |title=Board of Directors |work=Partners HealthCare System |access-date=2015-09-24 |archive-url=https://web.archive.org/web/20150712231934/https://www.partners.org/About/Company-Information/Leadership/Board-of-Directors.aspx# |archive-date=2015-07-12 |url-status=dead }}</ref><br>[[Fellows of Harvard Medical School]]<br>[[PhRMA|Pharmaceutical Research and Manufacturers of America]]<ref name=\"Verastem_2015\" />[[Biotechnology Industry Organization]]<ref name=\"Terrapinn\">{{cite conference | url=http://www.terrapinn.com/conference/world-orphan-drug-congress/speaker-henri-TERMEER.stm | title=Mr Henri Termeer: Chief Executive Officer, Former Genzyme |conference=Orphan Drug Congress |author=Terrapinn Holdings Ltd | date=2015 | accessdate=27 September 2015}}</ref><br>[[Moderna Therapeutics]] (2013-)\n|spouse       =Belinda Termeer\n|children     =Nicholas, Adriana\n|parents      = Jacques and Mary (Van Gorp) \n|website      =\n|signature    = \n|signature_alt= \n}}\n\n'''Henri A. Termeer''' (28 February 1946 \u2013 12 May 2017)<ref>{{Cite news|url=https://www.bostonglobe.com/metro/2017/05/13/henri-termeer-key-biotech-leader-who-built-genzyme-into-industry-giant-dies/HUbclNVfURdx1ARCH2OK1M/story.html|title=Henri A. Termeer, key biotech leader who built Genzyme into an industry giant, dies at 71|last=Marquard|first=Bryan|date=13 May 2017|work=The Boston Globe|access-date=13 May 2017|archive-url=https://web.archive.org/web/20170515135438/https://www.bostonglobe.com/metro/2017/05/13/henri-termeer-key-biotech-leader-who-built-genzyme-into-industry-giant-dies/HUbclNVfURdx1ARCH2OK1M/story.html|archive-date=2017-05-15|url-status=dead|last2=Weisman|first2=Robert}}</ref> was a Dutch [[biotechnology]] executive and entrepreneur who is considered a pioneer<ref name=\"Bloomberg_Private_equity_2011\" /> in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme.<ref name=\"Bloomberg_2010_pioneer\">{{citation |url=https://www.bloomberg.com/news/articles/2010-09-01/biotech-pioneer-who-priced-world-s-most-expensive-drugs-loses-genzyme-grip |title=Genzyme's Termeer, Biotechnology Pioneer, May Sell |date=1 September 2010 |accessdate=17 July 2015 |publisher=Bloomberg}}</ref> Termeer created a business model<ref name=\"Bloomberg_Private_equity_2011\" /> adopted by many others in the biotech industry by garnering steep prices\u2014 mainly from insurers and government payers\u2014 for therapies for rare genetic disorders<ref name=\"Bloomberg_Private_equity_2011\" /> known as [[orphan diseases]] that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness<ref name=\"institutional embeddedness_2005\" /> nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni.<ref name=\"McBride_2012\" /> Termeer is \"connected to 311 board members in 17 different organizations across 20 different industries\"<ref name=\"institutional embeddedness_2005\">{{cite book |editors=Stefano Breschi, Franco Malerba|authors=Porter, Kelley, Kjersten Bunker Whittington, and Walter W. Powell |chapter=The institutional embeddedness of high-tech regions: relational foundations of the Boston biotechnology community |title=Clusters, networks, and innovation |volume=261 |year=2005 }}</ref>{{rp|296}}<ref name=\"Bloomberg\" /><ref name=\"Biotech_History\">{{citation|title=Conversations with Henri Termeer |url=http://www.biotechhistory.org/wp-content/uploads/2014/07/LSF_OH_Henri_Termeer.pdf |archive-url=https://web.archive.org/web/20150721172046/http://www.biotechhistory.org/wp-content/uploads/2014/07/LSF_OH_Henri_Termeer.pdf |url-status=dead |archive-date=21 July 2015 |series=The Life Sciences Foundation Oral History Program |location=San Francisco |editor1=Gavin Rynne |editor2=Mark Jones |year=2013 |accessdate=7 July 2015 }} Oral history conducted by Ted Everson, Jennifer Dionisio, Pei Koay, and Arnold Thackray, May 23, December 7, 2006, August 2, 2007, December 18, 2008 & September 30, 2011</ref><ref name=\"Bloomberg\">{{citation |url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=345932&ticker=VSTM |publisher=Bloomberg |title=Verastem Inc (VSTM:NASDAQ GM) }}</ref> He has the legacy of being the \"longest-serving CEO in the biotechnology industry.<ref name=\"Bloomberg_Private_equity_2011\" />\n\nHe is an \"advocate for the Massachusetts biotech industry.\" \"To generate revenues to fund the research, Termeer entered into a number of side ventures including a chemical supplies business, a genetic counseling.\"<ref name=\"Strategic_Management_2014\">{{citation |title=Strategic Management: Theory & Cases: An Integrated Approach |authors=Charles Hill, Gareth Jones, Melissa Schilling |publisher=Cengage Learning |year=2014 }}</ref>{{rp|344}}\n\nTermeer was named as one of the top fifty leaders of thought in orphan drugs and rare diseases in a list published by Terrapin for the World Orphan Drug Congress which included \"eminent personalities that have advanced rare disease research.\"<ref name=\"WODC_2013\">{{citation |title=The top 50 thought-leaders in orphan drugs and rare disease |work=World Orphan Drug Congress USA |url= http://www.parentprojectmd.org/site/DocServer/top50thoughtleaders.pdf?docID=14443 |accessdate=20 July 2015 |date=2013}}</ref>\n\n{{quote|Henri was a biotech pioneer long before anyone knew what biotechs were. He founded Genzyme which is often said to have kick started today's orphan drug biotech M&A frenzy. Henri is definitely a mover/shaker in the biotech world and in the orphan drug space. He will always be known as the guy who figured out how to build a great business by making drugs for rare diseases. An inspiration and pioneer, many of his prot\u00e9g\u00e9s have since moved on to lead other successful companies in the rare disease and biotech space thanks to his influence.\"|World Orphan Drug Congress 2013}}\n\n==Early life==\n\n{{Empty section|date=September 2015}}\n\n==Education==\nTermeer \"studied economics at the Economische Hogeschool, Erasmus University, The Netherlands.<ref name=\"Biotech_History\" /> In 1973 he completed his MBA at Darden School at the [[University of Virginia]].<ref name=\"Biotech_History\" /> He received an honorary Doctor of Science  from the [[University of Massachusetts]].\n\n==Norvic==\nFrom 1969 to 1971 Termeer was a manager in management services in [[Norwich, United Kingdom]] at the Norvic Company, a show company.\n\n==Baxter International==\n\nHe began his career in the medical and healthcare product industry in 1973 when he started working as manager of international product planning for [[Deerfield, Illinois]]-based Travenol Laboratories Inc now [[Baxter International|Baxter]]. From 1975 to 1976 he was Baxter's international marketing manager. From 1976 to 1979 he was  general manager for Travenol GMBH in [[Munich]].\n\nFrom 1979 to 1981 he was executive vice president of the Hyland Therapeutics division of Baxter Travenol in [[Glendale, California]].<ref name=\"Bloomberg\" /> In the United States, plasma donors were paid for their time as the time commitment for regular donors is over 200 hours per year. Standards for donating plasma are set by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA).<ref>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=640&showFR=1&subpartNode=21:7.0.1.1.7.7 FDA > CDRH > CFR Title 21 Database Search<!-- Bot generated title -->]</ref> Almost all plasmapheresis in the US is performed by automated methods such as the Plasma Collection System (PCS2) made by [[Haemonetics]] or the Autopheresis-C (Auto-C) made by Fenwal, Inc., a former division of [[Baxter International]]. Termeer explained, \"This was the beginning of biotechnology. You took plasma and pulled it apart, fractionated it. Hyland sold Factor VIII, Factor IX, immunoglobulins, and albumin. The plasma was collected through ''plasmapheresis'' performed at collection centers all around the country. They paid people for plasma. They returned the red cells and paid for the plasma&nbsp;... There were ethical concerns about the payments. Very vulnerable people were being paid.\"<ref name=\"Biotech_History\" /> At that time Baxter was developing tests for [[Chagas disease]] which was very prevalent in Latin America, based on feedback indicating that it would be a big market. Termeer was sent to South America to \"figure out a way to set up the connections\" which was how Baxter operated. After meeting with the military and with the Center for Disease Control he called off the project as unprofitable.<ref name=\"Biotech_History\" />\n\nBack in Chicago he was Baxter's International Marketing Manager for several years with the \"Artificial Organs Division\u2014artificial kidneys, dialysis equipment, heart/lung machines, stuff like that.<ref name=\"Biotech_History\" /> This was a period of pioneering work in [[dialysis]] and in the development of heart and lung machines for open heart surgeries.<ref name=\"Biotech_History\" />\n\nMonica Higgins profiled Termeer as one of the alumni of the [[Baxter International|Baxter]] biopharmaceutical industryfirm, the 'Baxter boys'\u2014who produced many of the leaders of the burgeoning biopharmaceutical industry. By 2004 Henri Termeer's leadership at Genzyme was considered \"by many industry observers as exemplary and the firm, Genzyme, has often been seen as a role model for other firms in the industry.\"<ref name=\"Higgins_2004\">{{citation |author=Monica C. Higgins |title=Career Imprints: Creating Leaders Across An Industry |isbn=978-0-7879-7751-1 |pages=416 |date=March 2005 |publisher=Wiley}}</ref>  Higgins noted in 2004 that at that time, [t]he size and extent of Baxter's influence overall [was] difficult to ascertain since the biotechnology industry, with eight- to ten-year product development cycles, [was] still in its relative infancy.\"<ref name=\"Higgins_2004\" /><ref name=\"Shimasaki\">{{cite book |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech |editor=Craig Shimasaki |isbn=978-0-12-404730-3 |author=Henri A. Termeer |chapter=A Biotechnology Entrepreneur's Story: Advice to Future Entrepreneurs |pages=15\u201320 |date=April 2014 |publisher=Academic Press}}</ref>\n\nIn December 2011, the non-partisan organization [[Public Campaign#Reports|Public Campaign]] criticized Baxter for spending $10.45 million on [[lobbying]] and not paying any taxes during 2008\u20132010, instead getting $66 million in tax rebates, despite making a profit of $926 million.<ref name=\"Lobby_2011\">{{cite web|last=Portero |first=Ashley |title=30 Major U.S. Corporations Paid More to Lobby Congress Than Income Taxes, 2008\u20132010 |url=http://www.ibtimes.com/articles/264481/20111209/30-major-u-s-corporations-paid-lobby.htm |publisher=[[International Business Times]] |accessdate=December 26, 2011 |archiveurl=https://www.webcitation.org/64D9GyQG0 |archivedate=December 26, 2011 |url-status=dead }}</ref>\n\n==Genzyme==\n{{main|Genzyme}}\n\nAccording to the Boston Globe staff writer Robert Weisman,<ref name=\"bostonglobe_2015\" />\n\n{{quote|In the formative years of biotechnology, Genzyme was the industry's Apple, blazing a pathway for creating protein-based treatments for rare diseases.\"}}\n\nIn 1983 Termeer became chairman, CEO and president of Genzyme, a then two-year old start-up biotechnology company, located in Cambridge, Massachusetts.<ref name=\"Biotech_History\" /> At that time,<ref name=\"BostonGlobe_Termeer_Helman_2011\">{{citation |url=http://www.boston.com/business/healthcare/articles/2011/04/10/with_sale_genzyme_ceo_henri_a_termeer_reflects_on_building_a_biotech_pioneer/ |title=Going out on top |accessdate=17 July 2015 |date=10 April 2011 |publisher=Boston Globe |author=Henri A. Termeer }} as told to Scott Helman</ref>\n\n{{quote|Genzyme was just these professors from MIT and myself and some venture capitalists.\"|Termeer 2011}}\n\nIn 1985 he was appointed as their CEO. By 1988 he was Chairman of Genzyme.<ref name=\"Biotech_History\" /> During those years he held positions at Genzyme in Genzyme Tissue Repair, Strategic Planning & Capital Allocation Committee and Member of Risk Oversight Committee, Genzyme Oncology.<ref name=\"Bloomberg\" />\n\nWhen Genzyme needed a manufacturing facility, Termeer deliberately chose to remain in Massachusetts and use local contractors instead of using the pharmaceuticals cluster in the New Jersey and Philadelphia areas and their more specialized engineering firms. \"Massachusetts is home to a vibrant biotechnology cluster, which draws on the region's strong universities, medical centers, and venture capital firms.\"<ref name=\"Harvard_1998\">{{citation |title=Clusters and the New Economics of Competition |author=Michael E. Porter |date=December 1998 |journal=Harvard Business Review|url=https://hbr.org/1998/11/clusters-and-the-new-economics-of-competition}}</ref>\n\n[[Harvard Business School]] professor, [[Michael E. Porter]], a leading authority on competitive strategy and the competitiveness taught courses to newly appointed CEOs of very large corporations. Porter described Termeer's strategy as a cluster, the new economics of competition with all members benefiting from \"a strong base of supporting functions and institutions.\"<ref name=\"Harvard_1998\" /> Under Termeer's leadership, Genzyme built a \"critical mass\" for its \"cluster,\" in Massachusetts, a group of institutions that achieved unusual competitive success in the life sciences industry or biotechnology.<ref name=\"Harvard_1998\" />\n\n==Specialty pharmacy==\nIn 2005 Genzyme chose the [[specialty pharmacy]] division of PharmaCare, one of the largest pharmaceutical benefit management companies, as national network provider for [[Thyrogen]], Genzyme's specialty drug.<ref name=\"CVS Health\">{{cite web | url=http://cvshealth.com/content/pharmacare-included-genzymes-thyrogenr-distribution-network | title=PharmaCare Included in Genzyme's Thyrogen(R) Distribution Network | work=CVS Health | date=21 April 2005 | accessdate=24 September 2015}}</ref>\n\n===Cerezyme and Gaucher's Disease===\n\nIn 1991 the first version of Genzyme's [[orphan drug]] [[Alglucerase]] (brand name '''Ceredase'''), the only treatment for [[Gaucher's disease]],<ref name=Deegan>{{cite journal | author = Deegan PB, Cox TM | year = 2012 | title = Imiglucerase in the treatment of Gaucher disease: a history and perspective | journal = Drug Des Devel Ther. | volume = 6 | issue = | pages = 81\u2013106 | doi = 10.2147/DDDT.S14395 | pmid = 22563238 | pmc = 3340106 }}</ref> was approved by the FDA.<ref>World Health Organization.  [http://whqlibdoc.who.int/druginfo/DRUG_INFO_5_3_1991_p122-125.pdf Regulatory Matters] WHO Drug Information 5:3 1991. p 123</ref>\n\nTermeer explained in a 2005 interview for the [[Wall Street Journal]] that in 1991 one treatment of Cerezyme for one patient took 22,000 placentas annually to manufacture, a difficult and expensive procedure.<ref name=\"WSJ_2005\" />  According to the [[Congressional Office of Technology Assessment]] cerezyme cost $1.90 per unit including the cost of manufacturing, marketing and distribution. Genzyme charged $3.50 a unit.<ref name=\"WSJ_2005\" />  Imiglucerase was granted [[orphan drug]] status in the US, Australia, and Japan.<ref>{{cite web|url=http://www.orpha.net/consor/cgi-bin/Drugs_Search.php?lng=EN&data_id=23&Substance=Imiglucerase&search=Drugs_Search_SubstanceTradename&data_type=Product&diseaseType=Drug&Typ=Sub&title=&diseaseGroup=|title=Imiglucerase on Orpha.net: The portal for rare diseases and orphan drugs.}}</ref><ref name=\"pmid18627336\">{{cite journal |author=Weinreb NJ |title=Imiglucerase and its use for the treatment of Gaucher's disease |journal=Expert Opin Pharmacother |volume=9 |issue=11 |pages=1987\u20132000 |date=August 2008 |pmid=18627336 |doi=10.1517/14656566.9.11.1987 }}</ref><ref name=\"pmid17079176\">{{cite journal |vauthors=Starzyk K, Richards S, Yee J, Smith SE, Kingma W |title=The long-term international safety experience of imiglucerase therapy for Gaucher disease |journal=Mol. Genet. Metab. |volume=90 |issue=2 |pages=157\u201363 |date=February 2007 |pmid=17079176 |doi=10.1016/j.ymgme.2006.09.003 }}</ref>\n\nBy 1994 Genzyme had a new version of Cerezyme produced in genetically engineered cells in a process that was easier and cheaper.<ref name=\"WSJ_2005\" /> Although imiglucerase costs only less than 37 cents to manufacture, Genzyme charges $3.70 per unit making a 90% profit. The high price of the medication is part of Genzyme's business strategy in order for the biotech firm to undertake research and development for other drugs and to allow them to fund programs that distribute a small portion of production for free.<ref name=\"WSJ_2005\" /> So instead of lowering the price Termeer \"decided to use the extra revenue to give additional Cerezyme away free in countries that can't afford to pay the high price. He said Genzyme gives away about 10% of the drug it produces.\" In order to ensure patients had access to Cerezyme, by 2005 Genzyme had hired 34 people to help patients acquire insurance plans that would cover the cost of their drugs.<ref name=\"WSJ_2005\" /> By 2005 there was still no competition for the drug and with patients desperate for a therapy, most insurers were willing to pay.<ref name=\"WSJ_2005\" /> Genzyme used the profits \"to bring new treatments to market for two other rare diseases. It has purchased many small companies to expand into a diversified drug company with cancer, kidney disease and diagnostic products, among others.\"<ref name=\"WSJ_2005\" />\n\nBy 2005 although Cerezyme cost the average patient (including babies) $200,000 a year, it could cost a single adult patient as much as $520,000 a year even though it cost Genzyme less than $52,000 to manufacture.<ref name=\"WSJ_2005\">{{citation |url=https://www.wsj.com/articles/SB113210882766198549 |title=Why Genzyme Can Charge So Much for Cerezyme |author=Geeta Anand |publisher=The Wall Street Journal |date=November 2005 |accessdate=9 July 2015}}</ref>  In 2005 there were only about 4,500 patients on Cerezyme.<ref name=\"WSJ_2005\" />\n\n===Pompe disease===\nIn 1998, two of Crowley's children, Megan and Patrick, were diagnosed with a severe neuromuscular disorder, [[Glycogen storage disease type II]], also called Pompe's disease. In the face of the children's deteriorating health, the family moved to [[Princeton, New Jersey]] to be close to doctors specializing in the disease.<ref>Edelstein, Jeff. [http://www.trentonian.com/articles/2010/01/11/news/doc4b4a9df3030a9265998428.txt \"LOOK WHO'S TALKING: John Crowley, dad, entrepreneur, and subject of the upcoming film ''Extraordinary Measures''\"], ''[[The Trentonian]]'', January 11, 2010. Accessed February 17, 2011. \"Princeton's Crowley family, from left, Megan, Aileen, John, Patrick, and John Jr. John Crowley, a Princeton Township resident, is the father of two children with Pompe disease.\"</ref> Crowley worked at [[Bristol-Myers Squibb]], where he held a number of management positions. Frustrated with the slow pace of research on Pompe's disease, Crowley left Bristol-Myers Squibb in March 2000, and took a position as CEO of Novazyme Pharmaceuticals, a [[biotechnology]] research company located in [[Oklahoma City, Oklahoma|Oklahoma City]] founded by Dr.[[William Canfield]], that was conducting research on a new experimental treatment for the disease.<ref>[https://www.youtube.com/watch?v=khFGloa5Znk \"John Crowley On The Today Show 2001\"]. Youtube.com, September, 2001. Accessed June 16, 2008.</ref>\n\nBiotech executive [[John Crowley (biotech executive)|john Crowley]], whose two children were diagnosed in 1998 with [[Glycogen storage disease type II|Pompe's disease]], had been a major force behind the search for a cure. By 2001 Genzyme when acquired Novazyme, Termeer put Crowley in charge Genzyme's global Pompe program, the largest R&D effort in the company's history, from September 2001 until December 2002. At that time Genzyme was considered to be the world's third largest biotechnology company,<ref name=Lawyer>Crowley, John. [http://www.nd.edu/~ndlaw/alumni/ndlawyer/spring07/children.pdf \"To Save the Children\"]. ''Notre Dame Lawyer'', Spring 2007. Accessed April 4, 2008.</ref><ref name=Amicus>[http://investing.businessweek.com/research/stocks/people/person.asp?personId=1061285&symbol=FOLD.O Amicus Therapeutics, Inc. Executive Profile], ''[[BusinessWeek]]''. Accessed April 4, 2008.</ref> Genzyme's work eventually bore fruit and in January 2003, Crowley's children received the [[enzyme replacement therapy]] for Pompe disease developed by Genzyme. Crowley credits the experimental trial with saving his children's lives.<ref name=Lawyer/> The acquisition of Novazyme by Genzyme, and Crowley's fight to cure Pompe's Disease, was documented in the Harvard Business School Case Study, Novazyme: A Father's Love.<ref>[http://cb.hbsp.harvard.edu/cb/web/product_detail.seam;jsessionid=6DB873464F555239AAA24EA75B984650?E=36727&R=603048-PDF-ENG&conversationId=139298 \"A Father's Love: Novazyme Pharmaceuticals, Inc. \"]. Harvard.edu, October, 2002. Accessed June 14, 2011.</ref><ref>[http://viewer.zmags.com/publication/941184aa#/941184aa/59 \"Journey of the Heart\"]. PharmaVoice.com, January, 2009. Accessed April 8, 2009.</ref>\n\nAccording to Higgins by 2004 Henri Termeer's leadership at Genzyme was celebrated by a number of biotech industry observers as exemplary. Genzyme, in 2004 was seen as a role model for other biotechnology firms.<ref name=\"Higgins_2004\" />\n\nAccording to the Wall Street Journal, in 2004 Termeer earned a combined salary and bonus of $3 million. He also had \"options valued at between $12.6 million and $32 million in 10 years, based on appreciation of the company's stock of between 5% and 10% a year, according to the company's proxy.\"<ref name=\"WSJ_2005\" />\n\nIn 2007 Genzyme acquired [[Bioenvision]] and the rights to the North American market for [[clofarabine]],<ref name=\"AP_2007\">{{cite web| agency = Associated Press | date = October 22, 2007  | url = http://www.iht.com/articles/ap/2007/10/22/business/NA-FIN-US-Genzyme-Bioenvision.php| title = Genzyme Claims Victory in Prolonged Bid for Bioenvision| publisher = International Herald Tribune (France)| accessdate = November 10, 2007 }}</ref> (brand name '''Clofarex'''), designated by the [[Food and Drug Administration]] (FDA)  as an [[orphan drug]]<ref name=\"NCBI_2004\">{{citation |journal=Drugs in R&D |year=2004 |volume=5 |number=4 |pages=:213\u20137 |title=Clofarabine |pmid=15230627|doi=10.2165/00126839-200405040-00005 }}</ref>\n\nIn 2007 Termeer as CEO earned a salary of $2.5 million, and non-cash compensation worth $129 million.<ref name=\"Forbes_2007\">{{cite news | author = Forbes | date = December 2007| url = https://www.forbes.com/finance/mktguideapps/personinfo/FromPersonIdPersonTearsheet.jhtml?passedPersonId=222120| title = Henri Termeer Profile      | publisher = Henri Teemer profile      | accessdate = July 10, 2008}}</ref>\n\nFrom 2007 to 2008 under Termeer as CEO, Genzyme spent more than $8.2 million on [[lobbying]].  In 2009 alone, Genzyme had 10 different organizations with a total of 49 lobbyists working on its behalf.<ref name=\"lobby_groups_2008\">{{citation |url=http://www.opensecrets.org/lobby/clientsum.php?year=2008&lname=Genzyme+Corp&id= Genzyme Corp. |title=Client Profile: Summary |year=2008 |work=Center for Responsive Politics}}</ref>\n\nIn 1981, before Termeer had joined Genzyme, it was a small firm that \"employed 14 people in an office in Chinatown.\"<ref name=\"50_wealthiest_2006\" /> By 2006 Genzyme with Termeer as CEO Genzyme became a biotech powerhouse with a \"payroll of more than 8,000 in 70 offices and plants worldwide, making it the third-largest company of its kind.\"<ref name=\"50_wealthiest_2006\" /> In 2004 \"Termeer was the area's highest-paid CEO\" in 2004, with a \"total compensation package worth at least $37.9 million.\"<ref name=\"50_wealthiest_2006\">{{citation |url=http://www.bostonmagazine.com/2006/05/the-50-wealthiest-bostonians/ |title=The 50 Wealthiest Bostonians |author=Francis Storrs |publisher=Boston Magazin| date=March 2006 |accessdate=8 July 2015}}</ref> He was 42nd in the 2006 list of Boston's wealthiest with a networth of $342 million.<ref name=\"50_wealthiest_2006\" />\n\nIn June 2009 Genzyme experienced a manufacturing disaster  after contamination with Vesivirus 2117 at their  Allston, Massachusetts plant that resulted in shortages of Genzyme drugs including Cerezyme.<ref name=\"Boston_Globe_2009\">{{cite journal|url=http://www.boston.com/business/healthcare/articles/2009/06/17/genzyme_temporarily_halts_production_on_2_key_drugs/|title=Virus shuts Genzyme plant, holds up drugs for 8,000|journal=The Boston Globe|author1=Erin Ailworth |author2=Robert Weisman |date=June 17, 2009}}</ref><ref name=\"xconomy_2013\" /> Patients and shareholders depicted Genzyme corporate behaviour as irresponsible and arrogant.<ref name=\"xconomy_2013\" /> Genzyme was fined $175 million by the FDA for manufacturing deficiencies.<ref name=\"xconomy_2013\" /> Genzymes's competitors benefited<ref name=\"xconomy_2013\" /> and Genzyme stocks fell. As a result, 2011 Genzyme was acquired by Sanofi in an hostile takeover in October, 2011\u2014engineered in part by then-CEO of Sanofi, Christopher Viehbacher\u2014<ref name=\"Gillham\">{{cite book |title=Genes, Chromosomes, and Disease: From Simple Traits, to Complex Traits |author=Nicholas Wright Gillham |isbn=978-0137075447 |publisher=FT Press Science}}</ref>{{rp|219}} for more than $20 billion. Termeer retired.<ref name=\"McBride_2012\" /><ref name=\"xconomy_2013\" />\n\nWhen Termeer left Genzyme his payout was valued at about $138 million,<ref name=\"Bloomberg_Private_equity_2011\">{{citation |url=https://www.bloomberg.com/news/articles/2011-02-16/genzyme-s-termeer-may-follow-health-care-ceo-path-to-private-equity-firms |date=16 February 2011 |accessdate=17 July 2015 |publisher=Bloomberg |author=Meg Tirrell |title=Genzyme's Termeer May Follow Health Care CEO Path to Private Equity Firms}}</ref><ref name=\"xconomy_2013\">{{citation |url=http://www.xconomy.com/national/2013/05/13/henri-termeer-on-startups-drug-prices-and-getting-older-part-1/ |date=13 May 2013 |accessdate=9 July 2015 |title=Henri Termeer on Startups, Drug Prices, Getting Older (Part 1) |work=Xconomy |author=Luke Timmerman}}</ref> making him \"one of the biggest all-time winners in biotech.\"<ref name=\"Bloomberg_Private_equity_2011\" />\n\n==Biotechnology Industry Organization (BIO)==\n{{main|Biotechnology Industry Organization}}\nIn 1993 Termeer helped bring about the creation of Biotechnology Industry Organization through the merger of two associations created in the 1980s, the [[Association of Biotechnology Companies]] (ABC)\u2014an association of smaller start-ups and their business support network c\u2014  and the [[Industrial Biotechnology Association]] (IBA)\u2014 an organization for the larger biotech firms. Termeer was on the board of directors of IBA. Termeer was concerned about potential health-care and FDA reform following the election of Bill Clinton in 1992. He wanted the biotechnology industry to speak with one voice.<ref name=\"BIO\">{{citation |url=http://www3.bio.org/speeches/pubs/milestone03/termeer.asp |title=Henri A. Termeer Genzyme, 1995\u20131997 |publisher=Biotechnology Industry Organization |accessdate=8 July 2015 |location=Washington, D.C. |archive-url=https://web.archive.org/web/20150925092539/http://www3.bio.org/speeches/pubs/milestone03/termeer.asp# |archive-date=2015-09-25 |url-status=dead }}</ref> It was in 1997 while addressing 3,000 people at the BIO international meeting held in Houston that he realized that BIO needed to engage and include patient groups, religious groups, etc.<ref name=\"BIO\" /> Termeer claimed that BIO was more than lobbying. Under Termeer's leadership as BIO's CEO in 1997 the group successfully exerted pressure which culminated in passage of the [[Food and Drug Administration Modernization Act of 1997]] with criteria \"for fast-track drug development, allowed some drug approvals based on one pivotal trial, provided easier patient access to experimental drugs and devices, and renewed the Prescription Drug User Fee program.\" \"The act was very, very helpful,\" he said. \"We set up very good connections between BIO members and the FDA. I felt good about that.\"<ref name=\"BIO\" />\n\nIn 2002 Termeer predicted that biotechnology could raise profits that can fund future research. He spoke of Gaucher's disease.<ref name=\"MIT_video_2002\">{{citation |url=http://video.mit.edu/watch/biotechnology-will-it-create-a-new-industry-9842/ |title=Biotechnology - Will It Create a New Industry? |date=26 April 2002 |author=Henri A. Termeer |publisher=MIT |accessdate=17 July 2015 |format=video}}</ref>\n\n==New England Healthcare Institute==\n{{main|NEHI}}\nIn 2002 Termeer was instrumental in bringing together 20 other high-profile health care leaders, to found NEHI, a \"nonprofit, applied research health policy organization\",<ref name=\"verastem\">{{citation |url=http://www.verastem.com/about/directors.aspx#cw |title=About |work=Verastem}}</ref> as the \"New England Healthcare Institute.\"<ref name=\"Boger_2007\">{{citation |title=Building on a System of Outreach, Collaboration |author=Joshua Boger |publisher=Boston Globe |date=7 May 2007 |accessdate=8 July 2015|url=http://www.boston.com/news/globe/editorial_opinion/oped/articles/2007/05/07/building_on_a_system_of_outreach_collaboration/ }}</ref> including [[Joshua Boger]] of [[Vertex Pharmaceuticals]], Joseph B. Martin, MD, PhD, then [[Dean (education)|Dean]] of [[Harvard Medical School]], [[Samuel O. Thier]], MD, then CEO, [[Partners HealthCare]], Fred Telling, PhD, then VP of Corporate Policy and Strategic Management, [[Pfizer]] and [[Charles D. Baker, Jr.|Charlie Baker]], CEO, [[Harvard Pilgrim Health Care, Inc.|Harvard Pilgrim Health Care]]. NEHI members include biotech and pharmaceutical companies, academic health centers, hospitals, medical device companies, employers, payers, patient groups, and others.<ref name=\"Boger_2007\" /> Termeer is a Chairman Emeritus of the New England Healthcare Institute.\n\n==Massachusetts Council of Economic Advisors==\n\nIn 2008 Governor [[Deval Patrick]] appointed Termeer to the [[Massachusetts]] Council of Economic Advisors.<ref name=\"verastem\" />\n\n==Private equity==\n\nErik Gordon from Ann Arbor, a [[University of Michigan]] business professor, remarked on Termeer's success \"selling some of the world's most expensive medicines, priced from $200,000 to $300,000 a year\" and suggested that following his retirement from Genzyme in 2011, Termeer may be hired by private-equity firms to \"pitch deals. Ex-[[Wyeth]] CEO Bob Essner became a senior advisor with the [[Carlyle Group]]\u2014a \"behemoth in private-equity\"\u2014 on the firm's health-care investments.<ref name=\"Bob_Essner_2010\">{{citation |title=Ex-Wyeth CEO Bob Essner Moves to Private Equity's Carlyle Group |url=https://blogs.wsj.com/health/2010/04/08/ex-wyeth-ceo-bob-essner-moves-to-private-equitys-carlyle-group/ |author=James A. White |date=8 April 2010 |accessdate=17 July 2015 |publisher=Wall Street Journal}}</ref> Ex-CEO Fred Hassan of [[Schering-Plough|Schering-Plough Corporation]] has been working with private-equity firm [[Warburg Pincus LLC]].<ref name=\"Bob_Essner_2010\" /> \n{{quote|Henri is the guy you send out as your sales guy to get your real guys in the door. For an investment firm seeking biotech business, \"he would be a good guy to have. The CEO of a midmarket biotech company, they'll take a Henri Termeer call. They would all love to be Henri Termeer one day.\"|Erik Gordon 2011}}\n\n==AVEO oncology==\nBy 2012 Termeer was \"chairman of cancer drug specialists Aveo Oncology ($AVEO).<ref name=\"McBride_2012\" />\n\n==Prosensa==\n\nIn 2012 Termeer became strategic advisor for Prosensa, a venture-backed biotech<ref name=\"McBride_2012\" /> to provide advice on corporate strategy and to lobby for Protensa, bringing his \"experience in building Genzyme into a world leader in rare diseases.\" Prosensa's lead compound, a RNA therapy, 051, for an [[orphan disease]] known as [[Duchenne muscular dystrophy]] (DMD), is being developed by pharmaceutical giant, GlaxoSmithKline (GSK).<ref name=\"McBride_2012\">{{citation |title=Ex-Genzyme CEO Termeer returns to his roots at biotech Prosensa |date=13 December 2012 |author=Ryan McBride |url=http://www.fiercebiotech.com/story/ex-genzyme-ceo-termeer-returns-his-roots-biotech-prosensa/2012-12-13 |accessdate=8 July 2015 }}</ref>  GSK, which also makes major investments in rare diseases and orphan drugs, licensed 051 in 2009 for \"$25 million upfront and another $655 million in milestones.\"<ref name=\"fierce_15_2012\" /> \"Prosensa has a technology that could provide an array of RNA therapies for different variants of DMD, which affects about 1 in 3,500 male births and causes muscle wasting that leads to premature death.\"<ref name=\"McBride_2012\" /> In 2012 Prosensa was listed by the industry news monitor [[Fierce Biotech]]'s Fierce 15 as one of their top choices of pharmaceutical firms. Fierce Biotech covers biotechnology news including biopharma deals and clinical trials.<ref name=\"fierce_15_2012\">{{citation |url=http://www.fiercebiotech.com/special-reports/14-prosensa-2012-fierce-15 |title=Prosensa \u2013 2012 Fierce 15 |work=Fierce Biotech |date=19 September 2012 |accessdate=8 July 2015}}</ref>\n\nWhen Prosensa was founded in 2002 in Leiden, Netherlands with Hans Schikan as CEO, it was sustained for several years by patient groups\u2014like Charlie's Funds\u2014 a non-profit foundation which provided funds for scientific research on DMD.<ref name=\"idahomountainexpress\">{{cite news|url=http://www.mtexpress.com/index2.php?ID=2005129716|title=Facebook challenge offers $1 million for research|last=Plasse|first=Sabina Dana|date=January 22, 2010|work=[[Hailey, Idaho#Publications and media|Idaho Mountain Express]]|publisher=mtexpress.com|accessdate=16 June 2010}}{{dead link|date=November 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> Charlie's fund received over a million dollars from the documentary, [[Darius Goes West|Darius Goes West: The Roll of his Life]] a [[documentary film|documentary]] about a young DMD patient, Darius Weems' 2005 fund-raising road-trip across the [[United States]].\n<ref name=\"huffingtonpost\">{{cite news|url=http://www.huffingtonpost.com/jack-myers/ted-conference-2009-inspi_b_165594.html|title=TED Conference 2009: Inspiration and an Uplifting Spirit of Hope for Future Generations|last=Myers|first=Jack|date=February 10, 2009|work=[[Huffington Post]]|publisher=huffingtonpost.com|accessdate=17 June 2010}}</ref> When Prosensa CEO Hans Schikan served at Genzyme, he was \"responsible for the global marketing and strategy development of the genetic disease portfolio of orphan medicinal products, which includes the first treatment for Pompe disease.\" Prosensa, like Genzyme focuses on rare inherited diseases.<ref name=\"McBride_2012\" />\n\nBy 2012 Propensa had accumulated \u20ac55 million in venture capital and had \u20ac47 million in the bank. Prosensa's experience in fundraising over the years has provided a model for other rare disease startups.\"<ref name=\"fierce_15_2012\" />\n\n[[New Enterprise Associates]] contributed to Prosensa as its first entry into the European market.<ref name=\"fierce_15_2012\" /><ref name=\"Forbes_NEA_2012\">{{citation |title=New Enterprise Associates Closes $2.6 Billion In One Of Largest Venture Funds Ever |url=https://www.forbes.com/sites/tomiogeron/2012/07/25/new-enterprise-associates-closes-2-6-billion-in-one-of-largest-venture-funds-ever/ |work=Forbes |date=25 July 2012 |accessdate=8 July 2015}}</ref>\n\nProsensa employs over 80 people. \"The company attracted prominent life science ventures capitalists, including Life Science Partners, Abingworth and New Enterprise Associates (NEA), who led {{sic|a|hide=yes}} E23m round last January, bringing David Mott, General Partner of NEA and formerly a key executive with MedImmune to the Supervisory Board. Also added to this Supervisory Board in recent months has been Henri Termeer, former chairman and CEO of Genzyme for some three decades.\"<ref>http://www.liftstream.com/blog/prosensa-gsk-pool-resources-to-drive-drisapersen-in-duchenne/#.VZ1DdflViko</ref>\n\n==ProQR 2014==\n\nThe Dutch biotech startup [[ProQR|ProQR Therapeutics]] BV, a start-up from Leiden, \"licensed a compound from Boston scientists to develop a treatment\" for cystic fibrosis focusing on the role of messenger [[RNA]] in [[cystic fibrosis]]. In 2013 ProQR's CEO Daniel de Boer, whose three-year-old son suffers from cystic fibrosis was introduced to Termeer in Boston by Dutch biotechnology leader [[Dinko Valerio]].<ref name=\"Boston_Globe_2014\">{{citation |url=https://www.bostonglobe.com/business/2013/01/20/genzyme-henri-termeer-isn-exactly-settling-into-retirement/XTZKFMGnP2AewNMVkk1gbJ/story.html |title=Henri Termeer isn't exactly settling into retirement: Not content to rest on his laurels, the former Genzyme chief stays busy as a tireless advocate for the Massachusetts biotech industry |date=20 January 2013 |accessdate=8 July 2015 |publisher=Boston Globe |author=Robert Weisman |location=San Francisco}}</ref> Termeer and Valerio are part of a group of well-connected biotech executives financially backing the Dutch biotech ProQR which was focused on the role of messenger [[RNA]] in [[cystic fibrosis]] and has now pivoted to inherited retinal diseases including [[Leber congenital amaurosis]], [[Usher syndrome]] and [[retinitis pigmentosa]]. ProQR laid out its proposed terms for a $75 million IPO. ProQR planned \"to sell 6.3 million shares at $11 to $13 a share.\" ProQR is competing with [[Vertex Pharmaceuticals|Vertex]] whose lead drug would serve the same patient population. Termeer and his group \"expect to take the program all the way through to commercialization.\"<ref name=\"ProQR_2014\">{{citation |title=Termeer-backed ProQR lays out terms for $75M IPO |date=9 September 2014 |author=John Carrol |url=http://www.fiercebiotech.com/story/termeer-backed-proqr-lays-out-terms-75m-ipo/2014-09-09|publisher=Fierce Biotech}}</ref>\n\n==Moderna Therapeutics==\nIn April 2013 Termeer joined the board of directors of [[Moderna Therapeutics]], a Cambridge-based biotech company that is developing a platform technology for delivery of [[Messenger RNA|mRNA]].<ref name=BioWorld_2013>{{cite web|url=http://www.bioworld.com/content/moderna-makes-entrance-40m-round-mrna-work|author=Catherine Shaffer|date=December 6, 2013|title=Moderna Makes Entrance with $40M Round for mRNA Work|publisher=BioWorld|accessdate=Dec 11, 2013}}</ref><ref name=\"Moderna_2013\">{{citation |title=Henri A. Termeer Joins Moderna Therapeutics Board of Directors |url=http://www.modernatx.com/news-events/press-releases/henri-termeer-joins-moderna-therapeutics-board-directors |location=Cambridge, Mass. |date=30 April 2013 |accessdate=8 July 2015 |archive-url=https://web.archive.org/web/20150708235928/http://modernatx.com/news-events/press-releases/henri-termeer-joins-moderna-therapeutics-board-directors# |archive-date=2015-07-08 |url-status=dead }}</ref><ref name=Nature>{{cite journal|date=September 8, 2013|title=Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction|journal=Nature Biotechnology|volume=31|issue=10|doi=10.1038/nbt.2682|pages=898\u2013907|pmid=24013197|pmc=4058317|vauthors=Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, Sp\u00e4ter D, Xu H, Tabebordbar M, Gorbatov R, Sena B, Nahrendorf M, Briscoe DM, Li RA, Wagers AJ, Rossi DJ, Pu WT, Chien KR}}</ref> The company creates synthetic mRNA that can be injected into patients to help them create their own therapies. By December 2012 Moderna Therapeutics received $40 million \"financing led by Flagship Ventures and a consortium of private investors.\"<ref name=BioWorld_2013 />\n\n==CANbridge==\nIn September 2013 China's [[CANbridge]], which is commercializing Western clinical stage pharmaceutical products in China, appointed Termeer as Chief Advisor of their Life Sciences Advisory Board.<ref name=\"CANbridge\">{{citation |url=https://www.bio.org/canbridge-life-sciences-appoints-former-genzyme-ceo-henri-termeer-advisory-board |title=CANbridge Life Sciences Appoints Former Genzyme CEO, Henri Termeer, to Advisory Board |date=26 September 2013 |accessdate=8 July 2015 |location=Beijing |publisher=Business Wire }}{{Dead link|date=November 2018 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>\n\n==Mentorship==\nIn 2015, from his home office in Marblehead, Massachusetts overlooking [[Marblehead Harbor]], Termeer continues to mentor former Genzyme colleagues who are now CEOs of about two dozen smaller companies.<ref name=\"bostonglobe_2015\">{{citation |title=How Genzyme became a source of biotech executives |url=https://www.bostonglobe.com/business/2015/07/11/genzyme-family-tree-how-henri-termeer-spawned-network-genzyme-alums-leading-dozens-biotechs-from-cambridge-stockholm/Dkoz2zcLlNz3N6OZbOvN4L/story.html# |publisher=Boston Globe |date=12 July 2015 |accessdate=17 July 2015 |author=Robert Weisman}}</ref> Among this group of elite biotech entrepreneurs \u2014 the \"Genzyme diaspora\"\u2014  are Geoff McDonough, now CEO of [[Swedish Orphan Biovitrum AB]] of [[Stockholm]], Gail Maderis, who runs biotechnology firms and an industry trade group in the [[San Francisco Bay]] area, Tom Mathers, CEO at [[CoLucid Pharmaceuticals Inc]], Jeff Albers has a Cambridge-based startup, Blueprint Medicines Corporation and Greg Madison, CEO of New York's Keryx Biopharmaceuticals Inc.<ref name=\"bostonglobe_2015\" />\n\n==Awards==\n\n* 1990\u20131992 [[The Wall Street Transcript]] Gold Award\n* 1995 [[Success (magazine)|Success Magazine]]  'Renegade of the Year'\n* 1999 Golden Door award from the [[International Institute of New England]], an award that symbolizes the positive influence that immigrants have had on America.\n* 2003 Cor Vitae Award from the [[American Heart Association]]\n* In 2005 Genzyme received the [[National Medal of Technology and Innovation]], the highest honor awarded by the President of the United States for technological innovation. Termeer accepted the award on behalf of Genzyme \"For pioneering dramatic improvements in the health of thousands of patients with rare diseases and harnessing the promise of biotechnology to develop innovative new therapies.\"\n* 2007 [[Ernst & Young Entrepreneur of the Year Award]]\n* 2008 [[Biotechnology Heritage Award]], from the [[Biotechnology Industry Organization]] (BIO) and the [[Chemical Heritage Foundation]]<ref name=\"Biotechnology\">{{cite web|title=Biotechnology Heritage Award|url=https://www.sciencehistory.org/biotechnology-heritage-award|website=Science History Institute|accessdate=22 March 2018}}</ref><ref name=Krughoff>{{cite news|last=Krughoff|first=Tracy|title=Henri A. Termeer to Receive 2008 Biotechnology Heritage Award|url=http://www.bio.org/media/press-release/henri-termeer-receive-2008-biotechnology-heritage-award|accessdate=5 February 2014|publisher=BIO|date=15 June 2008}}</ref>\n\n===Global Genes RARE Project Champions of Hope===\n\nIn 2012 Termeer received the Lifetime Achievement Award  from Nicole Boice, founder and CEO, Global Genes R.A.R.E Project. He was honoured for leading Genzyme for nearly 30 years and helping \"to establish Massachusetts as a major center of industrial biotech research and development,\" for \"spearheading the development of rare disease treatments at a time when other pharmaceutical companies were focusing on drugs for much larger patient populations.\"<ref name=\"RARE\">{{citation |url=https://globalgenes.org/raredaily/global-genes-and-r-a-r-e-project-announce-tribute-to-champions-of-hope-gala-to-honor-rare-and-genetic-disease-pioneers-innovators-and-advocates/ |work=Global Genes |title=Global Genes and R.A.R.E. Project Announce Tribute to Champions of Hope\u2122 Gala to Honor Rare and Genetic Disease Pioneers, Innovators and Advocates |location=Dana Point, California|date=27 June 2012 |accessdate=9 July 2015}}</ref>\n\n==Academic==\n*1999 Fellow of the [[American Academy of Arts and Sciences]]\n* 1999 Genetic Disease Foundation Humanitarian Award\n* 2005 Honorary Fellowship at the British [[Royal College of Physicians]]\n\n==Other affiliations==\nTermeer is \"connected to 311 board members in 17 different organizations across 20 different industries\"<ref name=\"Bloomberg\" /> including [[AutoImmune]] Inc., [[Diacrin]], Inc., [[rEVO Biologics]], Inc., [[Allergan]] Inc., Genzyme Corporation, [[Tekla]] Life Sciences Investors, [[AVEO Pharmaceuticals]], Partners HealthCare System, [[Federal Reserve Bank of Boston]], [[Biotechnology Industry Organization]], [[Erasmus University]], [[Capital Royalty]], [[Federal Reserve Bank of Atlanta]], Colgate W. Darden Graduate School of Business Administration, [[Longwood Founders Management]], Verastem, [[Moderna Therapeutics]], [[ProQR Therapeutics]], [[CANbridge Life Sciences]] and the [[Fellows of Harvard Medical School]] Termeer serves on their board of directors.<ref name=\"Verastem_2015\" /><ref name=\"about-hms\">{{citation |url=https://hms.harvard.edu/about-hms/board-fellows |work=Fellows of Harvard Medical School |title=Board of Directors}}</ref>\n\n==Lysosomal Therapeutics==\n\nTermeer provided financial backing for Lysosomal Therapeutics or N.V.Lysosomal Therapeutics Inc., a fledgling biotech firm in Boston, developing a treatment for Parkinson's and other neurodegenerative diseases. According to Bloomberg Termeer is the founder of Lysosomal Therapeutics.<ref name=\"Bloomberg\" /> Termeer is mentoring Lysosomal Therapeutics CEO Dimitri Krainc, who is a neurologist at Massachusetts General Hospital and is originally from Slovenia. According to Krainc, he and Termeer are in \"contact by e-mail, phone, or in person weekly. ... \"It's fun to meet with Henri. He listens. He's got incredibly good judgment. And he's very focused on the patients.\"<ref name=\"Boston_Globe_2014\" />\n\n==Philanthropy==\n\n===Massachusetts General Hospital===\nTermeer $10 million donation.<ref name=\"McBride_2012\" /> funds research at the Henri and Belinda Termeer Center for Targeted Therapies at the [[Massachusetts General Hospital]] Cancer Center<ref name=\"McBride_2012\" /> where patients with early and advanced stage cancers enroll in \"its fast-growing portfolio of Phase I, Phase II and Phase III clinical trials.\"<ref name=\"MGH_2012\">{{citation |url=http://www.massgeneral.org/cancer/services/treatmentprograms.aspx?id=1544 |title=Treatment Programs |work=Massachusetts General Hospital}}</ref> Termeer is on the board of directors of the MGH and has served on numerous committees with Peter Slavin, Hospital director.<ref name=\"MGH_2012_opening\">{{citation |url=http://www.massgeneral.org/cancer/news/multimedia.aspx?id=629 |title=Termeer Center Opening Reception |date=2 October 2012 |accessdate=9 July 2015}}Talks by MGH President Dr. Peter Slavin, Mass General Cancer Center Director Dr. Daniel Haber, Termeer Center Director Dr. Keith Flaherty, patient John Murphy and donor Henri Termeer</ref>\n\nIn 2011 Termeer [[Cathy Minehan]], and [[Charles K. Gifford|Chad Gifford]]\u2014 fellow [[Partners HealthCare]] Board Members\u2014 co-chaired the Massachusetts General Hospital bicentennial. The gala, with 1,000 in attendance, also served as a fundraiser, raising approximately $1 million.<ref name=\"MGH_200\">{{citation |url=http://www.boston.com/2011/09/19/namesmgh/2Cxwc9DEpGQ3dfV407lzkI/story.html |title=Kissinger, Gifford, Termeer attend MGH bicentennial |date=19 September 2011 |publisher=Boston Globe |accessdate=16 July 2015}}</ref>\n\n==Popular culture==\nThe 2010 Hollywood film entitled [[Extraordinary Measures]] starring [[Harrison Ford]] as [[John Crowley (biotech executive)|John Crowley]]\n<ref name=\"NYT_Crowley\">{{citation |url=http://well.blogs.nytimes.com/2010/01/22/a-fathers-quest-to-cure-his-children/ |title=A Father's Quest to Cure His Children |author=Tara Parker-Pope |date=22 January 2010 |accessdate=14 July 2015 |work=New York Time blog}}</ref> working at Genzyme Corporation in Cambridge with Henri Termeer as CEO. It is allegedly based on the true story behind Genzyme's development of [[Myozyme]] for the treatment for Pompe disease, a rare enzyme deficiency. Boston Globe staffer Geeta Anand wrote a book on the topic called '''The Cure'''.<ref name=\"extraordinary_measures\">{{citation |title=Extraordinary Measures True Genzyme Story|date=16 January 2010 |accessdate=14 July 2014 |author=Jeffrey Newman |url=http://www.futurevigil.com/2010/01/film-extraordinary-measures-true-genzyme-story/ }}</ref>\n\nCrowley was profiled in ''[[The Wall Street Journal]]'' by [[Pulitzer Prize]]-winning journalist [[Geeta Anand]].<ref>[[Geeta Anand|Anand, Geeta]]. [https://www.wsj.com/articles/SB106184568337857300 \"For His Sick Kids, a Father Struggled to Develop a Cure\"]. ''[[The Wall Street Journal]]'', August 26, 2003. Accessed April 4, 2008.</ref>  Anand expanded the profile of Crowley into a book published in 2006, ''The Cure: How a Father Raised $100 Million&nbsp;\u2013 And Bucked the Medical Establishment&nbsp;\u2013 In a Quest to Save His Children'' ({{ISBN|978-0060734398}}).<ref>[http://magazine.nd.edu/news/9879-taking-matters-into-his-own-hands/ \"Taking Matters Into His Own Hands\"]. ''Notre Dame Magazine'', Spring 2007. Accessed November 28, 2011.</ref>\n\nHarrison Ford and Double Feature films optioned the rights to produce a film inspired by Anand's book and the Crowley family.<ref>[http://www.variety.com/article/VR1117987104.html?categoryid=13&cs=1 \"Crowley Lures Harrison Ford To CBS\"]. Variety.com, June 9, 2008. Accessed June 16, 2008.</ref> In April 2009, CBS Films began filming this major motion picture about the Crowley family's quest to save their children's lives. The film, titled ''[[Extraordinary Measures]]''<ref>{{cite web|url=https://us.imdb.com/title/tt1244659/|title=Extraordinary Measures|publisher=IMDb.com, Inc.|accessdate=2009-09-29}}</ref><ref>{{cite news|url=http://blogs.wweek.com/news/author/amesh/ |title=News and Culture: Brenden Fraser's Untitled Crowley Project Now Has (Another) Terrible Title |date=September 24, 2009 |work=[[Willamette Week]] |accessdate=2009-09-29 |url-status=dead |archiveurl=https://web.archive.org/web/20091023223408/http://blogs.wweek.com/news/author/amesh/ |archivedate=October 23, 2009 }}</ref> was released nationwide on January 22, 2010. Directed by [[Tom Vaughan (director)|Tom Vaughan]], ''Extraordinary Measures'' stars [[Brendan Fraser]] as John Crowley and [[Keri Russell]] as Aileen Crowley, and also executive producer [[Harrison Ford]] as \"Dr. Robert Stonehill\" who is a composite character based primarily on Dr. [[William Canfield]] and inspired as well by other doctors Crowley worked with.<ref>[http://www.genzyme.com/pompemovie/pompe-movie-faq.htm \"The Successful Effort to Develop Myozyme for Pompe Disease at Genzyme FAQs\"] {{webarchive |url=https://web.archive.org/web/20100125192214/http://www.genzyme.com/pompemovie/pompe-movie-faq.htm |date=January 25, 2010 }}</ref>\n\n==References==\n{{reflist}}\n\n{{authority control}}\n\n{{DEFAULTSORT:Termeer, Henri}}\n[[Category:1946 births]]\n[[Category:2017 deaths]]\n[[Category:University of Virginia alumni]]\n[[Category:American chief executives]]\n[[Category:Fellows of the American Academy of Arts and Sciences]]\n[[Category:People from Tilburg]]\n[[Category:Dutch emigrants to the United States]]\n[[Category:Erasmus University Rotterdam alumni]]\n", "text_old": "{{multiple issues|\n{{cleanup reorganize|date=May 2017}}\n{{update|date=May 2017}}\n{{like resume|date=May 2017}}\n{{lead too long|date=May 2017}}\n{{overly detailed|date=September 2015}}\n}}\n{{Infobox person\n|image        = Henri Termeer 2012 BIO Convention.jpg\n|image_size   =\n|alt          = \n|caption      = Termeer 2012\n|birth_date   = {{Birth date|1946|2|28|df=y}}<ref name=\"Biotech_History\" />\n|birth_place  = [[Tilburg]], [[Netherlands]]<ref name=\"Biotech_History\" />\n| death_date = {{Death date and age|2017|05|12|1946|02|28|df=y}}\n| death_place = [[Marblehead, Massachusetts]], U.S.\n|alma_mater   = [[Erasmus University]]\n|occupation   = Executive <br> [[Biotechnology]] entrepreneur\n|years_active = \n|net_worth    = \n|boards       = Verastem<br>[[Genzyme]] (1983\u20132011)<br>Federal Reserve Bank of Boston<br>[[Abiomed|ABIOMED Inc]]<br>Massachusetts Institute of Technology Corporation<br>[[Massachusetts General Hospital]]<br>[[Partners HealthCare|Partners HealthCare System]]<ref name=\"Verastem_2015\">{{citation |url=http://www.verastem.com/about/directors.aspx |work=Verastem | year=2015 |accessdate=9 July 2015 |title=Board of Directors}}</ref><ref name=\"partners\">{{citation |url=https://www.partners.org/About/Company-Information/Leadership/Board-of-Directors.aspx |title=Board of Directors |work=Partners HealthCare System |access-date=2015-09-24 |archive-url=https://web.archive.org/web/20150712231934/https://www.partners.org/About/Company-Information/Leadership/Board-of-Directors.aspx# |archive-date=2015-07-12 |url-status=dead }}</ref><br>[[Fellows of Harvard Medical School]]<br>[[PhRMA|Pharmaceutical Research and Manufacturers of America]]<ref name=\"Verastem_2015\" />[[Biotechnology Industry Organization]]<ref name=\"Terrapinn\">{{cite conference | url=http://www.terrapinn.com/conference/world-orphan-drug-congress/speaker-henri-TERMEER.stm | title=Mr Henri Termeer: Chief Executive Officer, Former Genzyme |conference=Orphan Drug Congress |author=Terrapinn Holdings Ltd | date=2015 | accessdate=27 September 2015}}</ref><br>[[Moderna Therapeutics]] (2013-)\n|spouse       =Belinda Termeer\n|children     =Nicholas, Adriana\n|parents      = Jacques and Mary (Van Gorp) \n|website      =\n|signature    = \n|signature_alt= \n}}\n\n'''Henri A. Termeer''' (28 February 1946 \u2013 12 May 2017)<ref>{{Cite news|url=https://www.bostonglobe.com/metro/2017/05/13/henri-termeer-key-biotech-leader-who-built-genzyme-into-industry-giant-dies/HUbclNVfURdx1ARCH2OK1M/story.html|title=Henri A. Termeer, key biotech leader who built Genzyme into an industry giant, dies at 71|last=Marquard|first=Bryan|date=13 May 2017|work=The Boston Globe|access-date=13 May 2017|archive-url=https://web.archive.org/web/20170515135438/https://www.bostonglobe.com/metro/2017/05/13/henri-termeer-key-biotech-leader-who-built-genzyme-into-industry-giant-dies/HUbclNVfURdx1ARCH2OK1M/story.html|archive-date=2017-05-15|url-status=dead|last2=Weisman|first2=Robert}}</ref> was a Dutch [[biotechnology]] executive and entrepreneur who is considered a pioneer<ref name=\"Bloomberg_Private_equity_2011\" /> in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme.<ref name=\"Bloomberg_2010_pioneer\">{{citation |url=https://www.bloomberg.com/news/articles/2010-09-01/biotech-pioneer-who-priced-world-s-most-expensive-drugs-loses-genzyme-grip |title=Genzyme's Termeer, Biotechnology Pioneer, May Sell |date=1 September 2010 |accessdate=17 July 2015 |publisher=Bloomberg}}</ref> Termeer created a business model<ref name=\"Bloomberg_Private_equity_2011\" /> adopted by many others in the biotech industry by garnering steep prices\u2014 mainly from insurers and government payers\u2014 for therapies for rare genetic disorders<ref name=\"Bloomberg_Private_equity_2011\" /> known as [[orphan diseases]] that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness<ref name=\"institutional embeddedness_2005\" /> nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, alumni.<ref name=\"McBride_2012\" /> Termeer is \"connected to 311 board members in 17 different organizations across 20 different industries\"<ref name=\"institutional embeddedness_2005\">{{cite book |editors=Stefano Breschi, Franco Malerba|authors=Porter, Kelley, Kjersten Bunker Whittington, and Walter W. Powell |chapter=The institutional embeddedness of high-tech regions: relational foundations of the Boston biotechnology community |title=Clusters, networks, and innovation |volume=261 |year=2005 }}</ref>{{rp|296}}<ref name=\"Bloomberg\" /><ref name=\"Biotech_History\">{{citation|title=Conversations with Henri Termeer |url=http://www.biotechhistory.org/wp-content/uploads/2014/07/LSF_OH_Henri_Termeer.pdf |archive-url=https://web.archive.org/web/20150721172046/http://www.biotechhistory.org/wp-content/uploads/2014/07/LSF_OH_Henri_Termeer.pdf |url-status=dead |archive-date=21 July 2015 |series=The Life Sciences Foundation Oral History Program |location=San Francisco |editor1=Gavin Rynne |editor2=Mark Jones |year=2013 |accessdate=7 July 2015 }} Oral history conducted by Ted Everson, Jennifer Dionisio, Pei Koay, and Arnold Thackray, May 23, December 7, 2006, August 2, 2007, December 18, 2008 & September 30, 2011</ref><ref name=\"Bloomberg\">{{citation |url=https://www.bloomberg.com/research/stocks/people/person.asp?personId=345932&ticker=VSTM |publisher=Bloomberg |title=Verastem Inc (VSTM:NASDAQ GM) }}</ref> He has the legacy of being the \"longest-serving CEO in the biotechnology industry.<ref name=\"Bloomberg_Private_equity_2011\" />\n\nHe is an \"advocate for the Massachusetts biotech industry.\" \"To generate revenues to fund the research, Termeer entered into a number of side ventures including a chemical supplies business, a genetic counseling.\"<ref name=\"Strategic_Management_2014\">{{citation |title=Strategic Management: Theory & Cases: An Integrated Approach |authors=Charles Hill, Gareth Jones, Melissa Schilling |publisher=Cengage Learning |year=2014 }}</ref>{{rp|344}}\n\nTermeer was named as one of the top fifty leaders of thought in orphan drugs and rare diseases in a list published by Terrapin for the World Orphan Drug Congress which included \"eminent personalities that have advanced rare disease research.\"<ref name=\"WODC_2013\">{{citation |title=The top 50 thought-leaders in orphan drugs and rare disease |work=World Orphan Drug Congress USA |url= http://www.parentprojectmd.org/site/DocServer/top50thoughtleaders.pdf?docID=14443 |accessdate=20 July 2015 |date=2013}}</ref>\n\n{{quote|Henri was a biotech pioneer long before anyone knew what biotechs were. He founded Genzyme which is often said to have kick started today's orphan drug biotech M&A frenzy. Henri is definitely a mover/shaker in the biotech world and in the orphan drug space. He will always be known as the guy who figured out how to build a great business by making drugs for rare diseases. An inspiration and pioneer, many of his prot\u00e9g\u00e9s have since moved on to lead other successful companies in the rare disease and biotech space thanks to his influence.\"|World Orphan Drug Congress 2013}}\n\n==Early life==\n\n{{Empty section|date=September 2015}}\n\n==Education==\nTermeer \"studied economics at the Economische Hogeschool, Erasmus University, The Netherlands.<ref name=\"Biotech_History\" /> In 1973 he completed his MBA at Darden School at the [[University of Virginia]].<ref name=\"Biotech_History\" /> He received an honorary Doctor of Science  from the [[University of Massachusetts]].\n\n==Norvic==\nFrom 1969 to 1971 Termeer was a manager in management services in [[Norwich, United Kingdom]] at the Norvic Company, a show company.\n\n==Baxter International==\n\nHe began his career in the medical and healthcare product industry in 1973 when he started working as manager of international product planning for [[Deerfield, Illinois]]-based Travenol Laboratories Inc now [[Baxter International|Baxter]]. From 1975 to 1976 he was Baxter's international marketing manager. From 1976 to 1979 he was  general manager for Travenol GMBH in [[Munich]].\n\nFrom 1979 to 1981 he was executive vice president of the Hyland Therapeutics division of Baxter Travenol in [[Glendale, California]].<ref name=\"Bloomberg\" /> In the United States, plasma donors were paid for their time as the time commitment for regular donors is over 200 hours per year. Standards for donating plasma are set by the [[Food and Drug Administration (United States)|U.S. Food and Drug Administration]] (FDA).<ref>[http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?CFRPart=640&showFR=1&subpartNode=21:7.0.1.1.7.7 FDA > CDRH > CFR Title 21 Database Search<!-- Bot generated title -->]</ref> Almost all plasmapheresis in the US is performed by automated methods such as the Plasma Collection System (PCS2) made by [[Haemonetics]] or the Autopheresis-C (Auto-C) made by Fenwal, Inc., a former division of [[Baxter International]]. Termeer explained, \"This was the beginning of biotechnology. You took plasma and pulled it apart, fractionated it. Hyland sold Factor VIII, Factor IX, immunoglobulins, and albumin. The plasma was collected through ''plasmapheresis'' performed at collection centers all around the country. They paid people for plasma. They returned the red cells and paid for the plasma&nbsp;... There were ethical concerns about the payments. Very vulnerable people were being paid.\"<ref name=\"Biotech_History\" /> At that time Baxter was developing tests for [[Chagas disease]] which was very prevalent in Latin America, based on feedback indicating that it would be a big market. Termeer was sent to South America to \"figure out a way to set up the connections\" which was how Baxter operated. After meeting with the military and with the Center for Disease Control he called off the project as unprofitable.<ref name=\"Biotech_History\" />\n\nBack in Chicago he was Baxter's International Marketing Manager for several years with the \"Artificial Organs Division\u2014artificial kidneys, dialysis equipment, heart/lung machines, stuff like that.<ref name=\"Biotech_History\" /> This was a period of pioneering work in [[dialysis]] and in the development of heart and lung machines for open heart surgeries.<ref name=\"Biotech_History\" />\n\nMonica Higgins profiled Termeer as one of the alumni of the [[Baxter International|Baxter]] biopharmaceutical industryfirm, the 'Baxter boys'\u2014who produced many of the leaders of the burgeoning biopharmaceutical industry. By 2004 Henri Termeer's leadership at Genzyme was considered \"by many industry observers as exemplary and the firm, Genzyme, has often been seen as a role model for other firms in the industry.\"<ref name=\"Higgins_2004\">{{citation |author=Monica C. Higgins |title=Career Imprints: Creating Leaders Across An Industry |isbn=978-0-7879-7751-1 |pages=416 |date=March 2005 |publisher=Wiley}}</ref>  Higgins noted in 2004 that at that time, [t]he size and extent of Baxter's influence overall [was] difficult to ascertain since the biotechnology industry, with eight- to ten-year product development cycles, [was] still in its relative infancy.\"<ref name=\"Higgins_2004\" /><ref name=\"Shimasaki\">{{cite book |title=Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech |editor=Craig Shimasaki |isbn=978-0-12-404730-3 |author=Henri A. Termeer |chapter=A Biotechnology Entrepreneur's Story: Advice to Future Entrepreneurs |pages=15\u201320 |date=April 2014 |publisher=Academic Press}}</ref>\n\nIn December 2011, the non-partisan organization [[Public Campaign#Reports|Public Campaign]] criticized Baxter for spending $10.45 million on [[lobbying]] and not paying any taxes during 2008\u20132010, instead getting $66 million in tax rebates, despite making a profit of $926 million.<ref name=\"Lobby_2011\">{{cite web|last=Portero |first=Ashley |title=30 Major U.S. Corporations Paid More to Lobby Congress Than Income Taxes, 2008\u20132010 |url=http://www.ibtimes.com/articles/264481/20111209/30-major-u-s-corporations-paid-lobby.htm |publisher=[[International Business Times]] |accessdate=December 26, 2011 |archiveurl=https://www.webcitation.org/64D9GyQG0 |archivedate=December 26, 2011 |url-status=dead }}</ref>\n\n==Genzyme==\n{{main|Genzyme}}\n\nAccording to the Boston Globe staff writer Robert Weisman,<ref name=\"bostonglobe_2015\" />\n\n{{quote|In the formative years of biotechnology, Genzyme was the industry's Apple, blazing a pathway for creating protein-based treatments for rare diseases.\"}}\n\nIn 1983 Termeer became chairman, CEO and president of Genzyme, a then two-year old start-up biotechnology company, located in Cambridge, Massachusetts.<ref name=\"Biotech_History\" /> At that time,<ref name=\"BostonGlobe_Termeer_Helman_2011\">{{citation |url=http://www.boston.com/business/healthcare/articles/2011/04/10/with_sale_genzyme_ceo_henri_a_termeer_reflects_on_building_a_biotech_pioneer/ |title=Going out on top |accessdate=17 July 2015 |date=10 April 2011 |publisher=Boston Globe |author=Henri A. Termeer }} as told to Scott Helman</ref>\n\n{{quote|Genzyme was just these professors from MIT and myself and some venture capitalists.\"|Termeer 2011}}\n\nIn 1985 he was appointed as their CEO. By 1988 he was Chairman of Genzyme.<ref name=\"Biotech_History\" /> During those years he held positions at Genzyme in Genzyme Tissue Repair, Strategic Planning & Capital Allocation Committee and Member of Risk Oversight Committee, Genzyme Oncology.<ref name=\"Bloomberg\" />\n\nWhen Genzyme needed a manufacturing facility, Termeer deliberately chose to remain in Massachusetts and use local contractors instead of using the pharmaceuticals cluster in the New Jersey and Philadelphia areas and their more specialized engineering firms. \"Massachusetts is home to a vibrant biotechnology cluster, which draws on the region's strong universities, medical centers, and venture capital firms.\"<ref name=\"Harvard_1998\">{{citation |title=Clusters and the New Economics of Competition |author=Michael E. Porter |date=December 1998 |journal=Harvard Business Review|url=https://hbr.org/1998/11/clusters-and-the-new-economics-of-competition}}</ref>\n\n[[Harvard Business School]] professor, [[Michael E. Porter]], a leading authority on competitive strategy and the competitiveness taught courses to newly appointed CEOs of very large corporations. Porter described Termeer's strategy as a cluster, the new economics of competition with all members benefiting from \"a strong base of supporting functions and institutions.\"<ref name=\"Harvard_1998\" /> Under Termeer's leadership, Genzyme built a \"critical mass\" for its \"cluster,\" in Massachusetts, a group of institutions that achieved unusual competitive success in the life sciences industry or biotechnology.<ref name=\"Harvard_1998\" />\n\n==Specialty pharmacy==\nIn 2005 Genzyme chose the [[specialty pharmacy]] division of PharmaCare, one of the largest pharmaceutical benefit management companies, as national network provider for [[Thyrogen]], Genzyme's specialty drug.<ref name=\"CVS Health\">{{cite web | url=http://cvshealth.com/content/pharmacare-included-genzymes-thyrogenr-distribution-network | title=PharmaCare Included in Genzyme's Thyrogen(R) Distribution Network | work=CVS Health | date=21 April 2005 | accessdate=24 September 2015}}</ref>\n\n===Cerezyme and Gaucher's Disease===\n\nIn 1991 the first version of Genzyme's [[orphan drug]] [[Alglucerase]] (brand name '''Ceredase'''), the only treatment for [[Gaucher's disease]],<ref name=Deegan>Deegan PB, Cox TM. Imiglucerase in the treatment of Gaucher disease: a history and perspective. Drug Des Devel Ther. 2012;6:81-106. doi: 10.2147/DDDT.S14395. Epub 2012 Apr 18. {{PMID|22563238}} (free full text)</ref> was approved by the FDA.<ref>World Health Organization.  [http://whqlibdoc.who.int/druginfo/DRUG_INFO_5_3_1991_p122-125.pdf Regulatory Matters] WHO Drug Information 5:3 1991. p 123</ref>\n\nTermeer explained in a 2005 interview for the [[Wall Street Journal]] that in 1991 one treatment of Cerezyme for one patient took 22,000 placentas annually to manufacture, a difficult and expensive procedure.<ref name=\"WSJ_2005\" />  According to the [[Congressional Office of Technology Assessment]] cerezyme cost $1.90 per unit including the cost of manufacturing, marketing and distribution. Genzyme charged $3.50 a unit.<ref name=\"WSJ_2005\" />  Imiglucerase was granted [[orphan drug]] status in the US, Australia, and Japan.<ref>{{cite web|url=http://www.orpha.net/consor/cgi-bin/Drugs_Search.php?lng=EN&data_id=23&Substance=Imiglucerase&search=Drugs_Search_SubstanceTradename&data_type=Product&diseaseType=Drug&Typ=Sub&title=&diseaseGroup=|title=Imiglucerase on Orpha.net: The portal for rare diseases and orphan drugs.}}</ref><ref name=\"pmid18627336\">{{cite journal |author=Weinreb NJ |title=Imiglucerase and its use for the treatment of Gaucher's disease |journal=Expert Opin Pharmacother |volume=9 |issue=11 |pages=1987\u20132000 |date=August 2008 |pmid=18627336 |doi=10.1517/14656566.9.11.1987 }}</ref><ref name=\"pmid17079176\">{{cite journal |vauthors=Starzyk K, Richards S, Yee J, Smith SE, Kingma W |title=The long-term international safety experience of imiglucerase therapy for Gaucher disease |journal=Mol. Genet. Metab. |volume=90 |issue=2 |pages=157\u201363 |date=February 2007 |pmid=17079176 |doi=10.1016/j.ymgme.2006.09.003 }}</ref>\n\nBy 1994 Genzyme had a new version of Cerezyme produced in genetically engineered cells in a process that was easier and cheaper.<ref name=\"WSJ_2005\" /> Although imiglucerase costs only less than 37 cents to manufacture, Genzyme charges $3.70 per unit making a 90% profit. The high price of the medication is part of Genzyme's business strategy in order for the biotech firm to undertake research and development for other drugs and to allow them to fund programs that distribute a small portion of production for free.<ref name=\"WSJ_2005\" /> So instead of lowering the price Termeer \"decided to use the extra revenue to give additional Cerezyme away free in countries that can't afford to pay the high price. He said Genzyme gives away about 10% of the drug it produces.\" In order to ensure patients had access to Cerezyme, by 2005 Genzyme had hired 34 people to help patients acquire insurance plans that would cover the cost of their drugs.<ref name=\"WSJ_2005\" /> By 2005 there was still no competition for the drug and with patients desperate for a therapy, most insurers were willing to pay.<ref name=\"WSJ_2005\" /> Genzyme used the profits \"to bring new treatments to market for two other rare diseases. It has purchased many small companies to expand into a diversified drug company with cancer, kidney disease and diagnostic products, among others.\"<ref name=\"WSJ_2005\" />\n\nBy 2005 although Cerezyme cost the average patient (including babies) $200,000 a year, it could cost a single adult patient as much as $520,000 a year even though it cost Genzyme less than $52,000 to manufacture.<ref name=\"WSJ_2005\">{{citation |url=https://www.wsj.com/articles/SB113210882766198549 |title=Why Genzyme Can Charge So Much for Cerezyme |author=Geeta Anand |publisher=The Wall Street Journal |date=November 2005 |accessdate=9 July 2015}}</ref>  In 2005 there were only about 4,500 patients on Cerezyme.<ref name=\"WSJ_2005\" />\n\n===Pompe disease===\nIn 1998, two of Crowley's children, Megan and Patrick, were diagnosed with a severe neuromuscular disorder, [[Glycogen storage disease type II]], also called Pompe's disease. In the face of the children's deteriorating health, the family moved to [[Princeton, New Jersey]] to be close to doctors specializing in the disease.<ref>Edelstein, Jeff. [http://www.trentonian.com/articles/2010/01/11/news/doc4b4a9df3030a9265998428.txt \"LOOK WHO'S TALKING: John Crowley, dad, entrepreneur, and subject of the upcoming film ''Extraordinary Measures''\"], ''[[The Trentonian]]'', January 11, 2010. Accessed February 17, 2011. \"Princeton's Crowley family, from left, Megan, Aileen, John, Patrick, and John Jr. John Crowley, a Princeton Township resident, is the father of two children with Pompe disease.\"</ref> Crowley worked at [[Bristol-Myers Squibb]], where he held a number of management positions. Frustrated with the slow pace of research on Pompe's disease, Crowley left Bristol-Myers Squibb in March 2000, and took a position as CEO of Novazyme Pharmaceuticals, a [[biotechnology]] research company located in [[Oklahoma City, Oklahoma|Oklahoma City]] founded by Dr.[[William Canfield]], that was conducting research on a new experimental treatment for the disease.<ref>[https://www.youtube.com/watch?v=khFGloa5Znk \"John Crowley On The Today Show 2001\"]. Youtube.com, September, 2001. Accessed June 16, 2008.</ref>\n\nBiotech executive [[John Crowley (biotech executive)|john Crowley]], whose two children were diagnosed in 1998 with [[Glycogen storage disease type II|Pompe's disease]], had been a major force behind the search for a cure. By 2001 Genzyme when acquired Novazyme, Termeer put Crowley in charge Genzyme's global Pompe program, the largest R&D effort in the company's history, from September 2001 until December 2002. At that time Genzyme was considered to be the world's third largest biotechnology company,<ref name=Lawyer>Crowley, John. [http://www.nd.edu/~ndlaw/alumni/ndlawyer/spring07/children.pdf \"To Save the Children\"]. ''Notre Dame Lawyer'', Spring 2007. Accessed April 4, 2008.</ref><ref name=Amicus>[http://investing.businessweek.com/research/stocks/people/person.asp?personId=1061285&symbol=FOLD.O Amicus Therapeutics, Inc. Executive Profile], ''[[BusinessWeek]]''. Accessed April 4, 2008.</ref> Genzyme's work eventually bore fruit and in January 2003, Crowley's children received the [[enzyme replacement therapy]] for Pompe disease developed by Genzyme. Crowley credits the experimental trial with saving his children's lives.<ref name=Lawyer/> The acquisition of Novazyme by Genzyme, and Crowley's fight to cure Pompe's Disease, was documented in the Harvard Business School Case Study, Novazyme: A Father's Love.<ref>[http://cb.hbsp.harvard.edu/cb/web/product_detail.seam;jsessionid=6DB873464F555239AAA24EA75B984650?E=36727&R=603048-PDF-ENG&conversationId=139298 \"A Father's Love: Novazyme Pharmaceuticals, Inc. \"]. Harvard.edu, October, 2002. Accessed June 14, 2011.</ref><ref>[http://viewer.zmags.com/publication/941184aa#/941184aa/59 \"Journey of the Heart\"]. PharmaVoice.com, January, 2009. Accessed April 8, 2009.</ref>\n\nAccording to Higgins by 2004 Henri Termeer's leadership at Genzyme was celebrated by a number of biotech industry observers as exemplary. Genzyme, in 2004 was seen as a role model for other biotechnology firms.<ref name=\"Higgins_2004\" />\n\nAccording to the Wall Street Journal, in 2004 Termeer earned a combined salary and bonus of $3 million. He also had \"options valued at between $12.6 million and $32 million in 10 years, based on appreciation of the company's stock of between 5% and 10% a year, according to the company's proxy.\"<ref name=\"WSJ_2005\" />\n\nIn 2007 Genzyme acquired [[Bioenvision]] and the rights to the North American market for [[clofarabine]],<ref name=\"AP_2007\">{{cite web| agency = Associated Press | date = October 22, 2007  | url = http://www.iht.com/articles/ap/2007/10/22/business/NA-FIN-US-Genzyme-Bioenvision.php| title = Genzyme Claims Victory in Prolonged Bid for Bioenvision| publisher = International Herald Tribune (France)| accessdate = November 10, 2007 }}</ref> (brand name '''Clofarex'''), designated by the [[Food and Drug Administration]] (FDA)  as an [[orphan drug]]<ref name=\"NCBI_2004\">{{citation |journal=Drugs in R&D |year=2004 |volume=5 |number=4 |pages=:213\u20137 |title=Clofarabine |pmid=15230627|doi=10.2165/00126839-200405040-00005 }}</ref>\n\nIn 2007 Termeer as CEO earned a salary of $2.5 million, and non-cash compensation worth $129 million.<ref name=\"Forbes_2007\">{{cite news | author = Forbes | date = December 2007| url = https://www.forbes.com/finance/mktguideapps/personinfo/FromPersonIdPersonTearsheet.jhtml?passedPersonId=222120| title = Henri Termeer Profile      | publisher = Henri Teemer profile      | accessdate = July 10, 2008}}</ref>\n\nFrom 2007 to 2008 under Termeer as CEO, Genzyme spent more than $8.2 million on [[lobbying]].  In 2009 alone, Genzyme had 10 different organizations with a total of 49 lobbyists working on its behalf.<ref name=\"lobby_groups_2008\">{{citation |url=http://www.opensecrets.org/lobby/clientsum.php?year=2008&lname=Genzyme+Corp&id= Genzyme Corp. |title=Client Profile: Summary |year=2008 |work=Center for Responsive Politics}}</ref>\n\nIn 1981, before Termeer had joined Genzyme, it was a small firm that \"employed 14 people in an office in Chinatown.\"<ref name=\"50_wealthiest_2006\" /> By 2006 Genzyme with Termeer as CEO Genzyme became a biotech powerhouse with a \"payroll of more than 8,000 in 70 offices and plants worldwide, making it the third-largest company of its kind.\"<ref name=\"50_wealthiest_2006\" /> In 2004 \"Termeer was the area's highest-paid CEO\" in 2004, with a \"total compensation package worth at least $37.9 million.\"<ref name=\"50_wealthiest_2006\">{{citation |url=http://www.bostonmagazine.com/2006/05/the-50-wealthiest-bostonians/ |title=The 50 Wealthiest Bostonians |author=Francis Storrs |publisher=Boston Magazin| date=March 2006 |accessdate=8 July 2015}}</ref> He was 42nd in the 2006 list of Boston's wealthiest with a networth of $342 million.<ref name=\"50_wealthiest_2006\" />\n\nIn June 2009 Genzyme experienced a manufacturing disaster  after contamination with Vesivirus 2117 at their  Allston, Massachusetts plant that resulted in shortages of Genzyme drugs including Cerezyme.<ref name=\"Boston_Globe_2009\">{{cite journal|url=http://www.boston.com/business/healthcare/articles/2009/06/17/genzyme_temporarily_halts_production_on_2_key_drugs/|title=Virus shuts Genzyme plant, holds up drugs for 8,000|journal=The Boston Globe|author1=Erin Ailworth |author2=Robert Weisman |date=June 17, 2009}}</ref><ref name=\"xconomy_2013\" /> Patients and shareholders depicted Genzyme corporate behaviour as irresponsible and arrogant.<ref name=\"xconomy_2013\" /> Genzyme was fined $175 million by the FDA for manufacturing deficiencies.<ref name=\"xconomy_2013\" /> Genzymes's competitors benefited<ref name=\"xconomy_2013\" /> and Genzyme stocks fell. As a result, 2011 Genzyme was acquired by Sanofi in an hostile takeover in October, 2011\u2014engineered in part by then-CEO of Sanofi, Christopher Viehbacher\u2014<ref name=\"Gillham\">{{cite book |title=Genes, Chromosomes, and Disease: From Simple Traits, to Complex Traits |author=Nicholas Wright Gillham |isbn=978-0137075447 |publisher=FT Press Science}}</ref>{{rp|219}} for more than $20 billion. Termeer retired.<ref name=\"McBride_2012\" /><ref name=\"xconomy_2013\" />\n\nWhen Termeer left Genzyme his payout was valued at about $138 million,<ref name=\"Bloomberg_Private_equity_2011\">{{citation |url=https://www.bloomberg.com/news/articles/2011-02-16/genzyme-s-termeer-may-follow-health-care-ceo-path-to-private-equity-firms |date=16 February 2011 |accessdate=17 July 2015 |publisher=Bloomberg |author=Meg Tirrell |title=Genzyme's Termeer May Follow Health Care CEO Path to Private Equity Firms}}</ref><ref name=\"xconomy_2013\">{{citation |url=http://www.xconomy.com/national/2013/05/13/henri-termeer-on-startups-drug-prices-and-getting-older-part-1/ |date=13 May 2013 |accessdate=9 July 2015 |title=Henri Termeer on Startups, Drug Prices, Getting Older (Part 1) |work=Xconomy |author=Luke Timmerman}}</ref> making him \"one of the biggest all-time winners in biotech.\"<ref name=\"Bloomberg_Private_equity_2011\" />\n\n==Biotechnology Industry Organization (BIO)==\n{{main|Biotechnology Industry Organization}}\nIn 1993 Termeer helped bring about the creation of Biotechnology Industry Organization through the merger of two associations created in the 1980s, the [[Association of Biotechnology Companies]] (ABC)\u2014an association of smaller start-ups and their business support network c\u2014  and the [[Industrial Biotechnology Association]] (IBA)\u2014 an organization for the larger biotech firms. Termeer was on the board of directors of IBA. Termeer was concerned about potential health-care and FDA reform following the election of Bill Clinton in 1992. He wanted the biotechnology industry to speak with one voice.<ref name=\"BIO\">{{citation |url=http://www3.bio.org/speeches/pubs/milestone03/termeer.asp |title=Henri A. Termeer Genzyme, 1995\u20131997 |publisher=Biotechnology Industry Organization |accessdate=8 July 2015 |location=Washington, D.C. |archive-url=https://web.archive.org/web/20150925092539/http://www3.bio.org/speeches/pubs/milestone03/termeer.asp# |archive-date=2015-09-25 |url-status=dead }}</ref> It was in 1997 while addressing 3,000 people at the BIO international meeting held in Houston that he realized that BIO needed to engage and include patient groups, religious groups, etc.<ref name=\"BIO\" /> Termeer claimed that BIO was more than lobbying. Under Termeer's leadership as BIO's CEO in 1997 the group successfully exerted pressure which culminated in passage of the [[Food and Drug Administration Modernization Act of 1997]] with criteria \"for fast-track drug development, allowed some drug approvals based on one pivotal trial, provided easier patient access to experimental drugs and devices, and renewed the Prescription Drug User Fee program.\" \"The act was very, very helpful,\" he said. \"We set up very good connections between BIO members and the FDA. I felt good about that.\"<ref name=\"BIO\" />\n\nIn 2002 Termeer predicted that biotechnology could raise profits that can fund future research. He spoke of Gaucher's disease.<ref name=\"MIT_video_2002\">{{citation |url=http://video.mit.edu/watch/biotechnology-will-it-create-a-new-industry-9842/ |title=Biotechnology - Will It Create a New Industry? |date=26 April 2002 |author=Henri A. Termeer |publisher=MIT |accessdate=17 July 2015 |format=video}}</ref>\n\n==New England Healthcare Institute==\n{{main|NEHI}}\nIn 2002 Termeer was instrumental in bringing together 20 other high-profile health care leaders, to found NEHI, a \"nonprofit, applied research health policy organization\",<ref name=\"verastem\">{{citation |url=http://www.verastem.com/about/directors.aspx#cw |title=About |work=Verastem}}</ref> as the \"New England Healthcare Institute.\"<ref name=\"Boger_2007\">{{citation |title=Building on a System of Outreach, Collaboration |author=Joshua Boger |publisher=Boston Globe |date=7 May 2007 |accessdate=8 July 2015|url=http://www.boston.com/news/globe/editorial_opinion/oped/articles/2007/05/07/building_on_a_system_of_outreach_collaboration/ }}</ref> including [[Joshua Boger]] of [[Vertex Pharmaceuticals]], Joseph B. Martin, MD, PhD, then [[Dean (education)|Dean]] of [[Harvard Medical School]], [[Samuel O. Thier]], MD, then CEO, [[Partners HealthCare]], Fred Telling, PhD, then VP of Corporate Policy and Strategic Management, [[Pfizer]] and [[Charles D. Baker, Jr.|Charlie Baker]], CEO, [[Harvard Pilgrim Health Care, Inc.|Harvard Pilgrim Health Care]]. NEHI members include biotech and pharmaceutical companies, academic health centers, hospitals, medical device companies, employers, payers, patient groups, and others.<ref name=\"Boger_2007\" /> Termeer is a Chairman Emeritus of the New England Healthcare Institute.\n\n==Massachusetts Council of Economic Advisors==\n\nIn 2008 Governor [[Deval Patrick]] appointed Termeer to the [[Massachusetts]] Council of Economic Advisors.<ref name=\"verastem\" />\n\n==Private equity==\n\nErik Gordon from Ann Arbor, a [[University of Michigan]] business professor, remarked on Termeer's success \"selling some of the world's most expensive medicines, priced from $200,000 to $300,000 a year\" and suggested that following his retirement from Genzyme in 2011, Termeer may be hired by private-equity firms to \"pitch deals. Ex-[[Wyeth]] CEO Bob Essner became a senior advisor with the [[Carlyle Group]]\u2014a \"behemoth in private-equity\"\u2014 on the firm's health-care investments.<ref name=\"Bob_Essner_2010\">{{citation |title=Ex-Wyeth CEO Bob Essner Moves to Private Equity's Carlyle Group |url=https://blogs.wsj.com/health/2010/04/08/ex-wyeth-ceo-bob-essner-moves-to-private-equitys-carlyle-group/ |author=James A. White |date=8 April 2010 |accessdate=17 July 2015 |publisher=Wall Street Journal}}</ref> Ex-CEO Fred Hassan of [[Schering-Plough|Schering-Plough Corporation]] has been working with private-equity firm [[Warburg Pincus LLC]].<ref name=\"Bob_Essner_2010\" /> \n{{quote|Henri is the guy you send out as your sales guy to get your real guys in the door. For an investment firm seeking biotech business, \"he would be a good guy to have. The CEO of a midmarket biotech company, they'll take a Henri Termeer call. They would all love to be Henri Termeer one day.\"|Erik Gordon 2011}}\n\n==AVEO oncology==\nBy 2012 Termeer was \"chairman of cancer drug specialists Aveo Oncology ($AVEO).<ref name=\"McBride_2012\" />\n\n==Prosensa==\n\nIn 2012 Termeer became strategic advisor for Prosensa, a venture-backed biotech<ref name=\"McBride_2012\" /> to provide advice on corporate strategy and to lobby for Protensa, bringing his \"experience in building Genzyme into a world leader in rare diseases.\" Prosensa's lead compound, a RNA therapy, 051, for an [[orphan disease]] known as [[Duchenne muscular dystrophy]] (DMD), is being developed by pharmaceutical giant, GlaxoSmithKline (GSK).<ref name=\"McBride_2012\">{{citation |title=Ex-Genzyme CEO Termeer returns to his roots at biotech Prosensa |date=13 December 2012 |author=Ryan McBride |url=http://www.fiercebiotech.com/story/ex-genzyme-ceo-termeer-returns-his-roots-biotech-prosensa/2012-12-13 |accessdate=8 July 2015 }}</ref>  GSK, which also makes major investments in rare diseases and orphan drugs, licensed 051 in 2009 for \"$25 million upfront and another $655 million in milestones.\"<ref name=\"fierce_15_2012\" /> \"Prosensa has a technology that could provide an array of RNA therapies for different variants of DMD, which affects about 1 in 3,500 male births and causes muscle wasting that leads to premature death.\"<ref name=\"McBride_2012\" /> In 2012 Prosensa was listed by the industry news monitor [[Fierce Biotech]]'s Fierce 15 as one of their top choices of pharmaceutical firms. Fierce Biotech covers biotechnology news including biopharma deals and clinical trials.<ref name=\"fierce_15_2012\">{{citation |url=http://www.fiercebiotech.com/special-reports/14-prosensa-2012-fierce-15 |title=Prosensa \u2013 2012 Fierce 15 |work=Fierce Biotech |date=19 September 2012 |accessdate=8 July 2015}}</ref>\n\nWhen Prosensa was founded in 2002 in Leiden, Netherlands with Hans Schikan as CEO, it was sustained for several years by patient groups\u2014like Charlie's Funds\u2014 a non-profit foundation which provided funds for scientific research on DMD.<ref name=\"idahomountainexpress\">{{cite news|url=http://www.mtexpress.com/index2.php?ID=2005129716|title=Facebook challenge offers $1 million for research|last=Plasse|first=Sabina Dana|date=January 22, 2010|work=[[Hailey, Idaho#Publications and media|Idaho Mountain Express]]|publisher=mtexpress.com|accessdate=16 June 2010}}{{dead link|date=November 2017 |bot=InternetArchiveBot |fix-attempted=yes }}</ref> Charlie's fund received over a million dollars from the documentary, [[Darius Goes West|Darius Goes West: The Roll of his Life]] a [[documentary film|documentary]] about a young DMD patient, Darius Weems' 2005 fund-raising road-trip across the [[United States]].\n<ref name=\"huffingtonpost\">{{cite news|url=http://www.huffingtonpost.com/jack-myers/ted-conference-2009-inspi_b_165594.html|title=TED Conference 2009: Inspiration and an Uplifting Spirit of Hope for Future Generations|last=Myers|first=Jack|date=February 10, 2009|work=[[Huffington Post]]|publisher=huffingtonpost.com|accessdate=17 June 2010}}</ref> When Prosensa CEO Hans Schikan served at Genzyme, he was \"responsible for the global marketing and strategy development of the genetic disease portfolio of orphan medicinal products, which includes the first treatment for Pompe disease.\" Prosensa, like Genzyme focuses on rare inherited diseases.<ref name=\"McBride_2012\" />\n\nBy 2012 Propensa had accumulated \u20ac55 million in venture capital and had \u20ac47 million in the bank. Prosensa's experience in fundraising over the years has provided a model for other rare disease startups.\"<ref name=\"fierce_15_2012\" />\n\n[[New Enterprise Associates]] contributed to Prosensa as its first entry into the European market.<ref name=\"fierce_15_2012\" /><ref name=\"Forbes_NEA_2012\">{{citation |title=New Enterprise Associates Closes $2.6 Billion In One Of Largest Venture Funds Ever |url=https://www.forbes.com/sites/tomiogeron/2012/07/25/new-enterprise-associates-closes-2-6-billion-in-one-of-largest-venture-funds-ever/ |work=Forbes |date=25 July 2012 |accessdate=8 July 2015}}</ref>\n\nProsensa employs over 80 people. \"The company attracted prominent life science ventures capitalists, including Life Science Partners, Abingworth and New Enterprise Associates (NEA), who led {{sic|a|hide=yes}} E23m round last January, bringing David Mott, General Partner of NEA and formerly a key executive with MedImmune to the Supervisory Board. Also added to this Supervisory Board in recent months has been Henri Termeer, former chairman and CEO of Genzyme for some three decades.\"<ref>http://www.liftstream.com/blog/prosensa-gsk-pool-resources-to-drive-drisapersen-in-duchenne/#.VZ1DdflViko</ref>\n\n==ProQR 2014==\n\nThe Dutch biotech startup [[ProQR|ProQR Therapeutics]] BV, a start-up from Leiden, \"licensed a compound from Boston scientists to develop a treatment\" for cystic fibrosis focusing on the role of messenger [[RNA]] in [[cystic fibrosis]]. In 2013 ProQR's CEO Daniel de Boer, whose three-year-old son suffers from cystic fibrosis was introduced to Termeer in Boston by Dutch biotechnology leader [[Dinko Valerio]].<ref name=\"Boston_Globe_2014\">{{citation |url=https://www.bostonglobe.com/business/2013/01/20/genzyme-henri-termeer-isn-exactly-settling-into-retirement/XTZKFMGnP2AewNMVkk1gbJ/story.html |title=Henri Termeer isn't exactly settling into retirement: Not content to rest on his laurels, the former Genzyme chief stays busy as a tireless advocate for the Massachusetts biotech industry |date=20 January 2013 |accessdate=8 July 2015 |publisher=Boston Globe |author=Robert Weisman |location=San Francisco}}</ref> Termeer and Valerio are part of a group of well-connected biotech executives financially backing the Dutch biotech ProQR which was focused on the role of messenger [[RNA]] in [[cystic fibrosis]] and has now pivoted to inherited retinal diseases including [[Leber congenital amaurosis]], [[Usher syndrome]] and [[Retinitis pigmentosa|retinitis pigmentosa.]] ProQR laid out its proposed terms for a $75 million IPO. ProQR planned \"to sell 6.3 million shares at $11 to $13 a share.\" ProQR is competing with [[Vertex Pharmaceuticals|Vertex]] whose lead drug would serve the same patient population. Termeer and his group \"expect to take the program all the way through to commercialization.\"<ref name=\"ProQR_2014\">{{citation |title=Termeer-backed ProQR lays out terms for $75M IPO |date=9 September 2014 |author=John Carrol |url=http://www.fiercebiotech.com/story/termeer-backed-proqr-lays-out-terms-75m-ipo/2014-09-09|publisher=Fierce Biotech}}</ref>\n\n==Moderna Therapeutics==\nIn April 2013 Termeer joined the board of directors of [[Moderna Therapeutics]], a Cambridge-based biotech company that is developing a platform technology for delivery of [[Messenger RNA|mRNA]].<ref name=BioWorld_2013>{{cite web|url=http://www.bioworld.com/content/moderna-makes-entrance-40m-round-mrna-work|author=Catherine Shaffer|date=December 6, 2013|title=Moderna Makes Entrance with $40M Round for mRNA Work|publisher=BioWorld|accessdate=Dec 11, 2013}}</ref><ref name=\"Moderna_2013\">{{citation |title=Henri A. Termeer Joins Moderna Therapeutics Board of Directors |url=http://www.modernatx.com/news-events/press-releases/henri-termeer-joins-moderna-therapeutics-board-directors |location=Cambridge, Mass. |date=30 April 2013 |accessdate=8 July 2015 |archive-url=https://web.archive.org/web/20150708235928/http://modernatx.com/news-events/press-releases/henri-termeer-joins-moderna-therapeutics-board-directors# |archive-date=2015-07-08 |url-status=dead }}</ref><ref name=Nature>{{cite journal|date=September 8, 2013|title=Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction|journal=Nature Biotechnology|volume=31|issue=10|doi=10.1038/nbt.2682|pages=898\u2013907|pmid=24013197|pmc=4058317|vauthors=Zangi L, Lui KO, von Gise A, Ma Q, Ebina W, Ptaszek LM, Sp\u00e4ter D, Xu H, Tabebordbar M, Gorbatov R, Sena B, Nahrendorf M, Briscoe DM, Li RA, Wagers AJ, Rossi DJ, Pu WT, Chien KR}}</ref> The company creates synthetic mRNA that can be injected into patients to help them create their own therapies. By December 2012 Moderna Therapeutics received $40 million \"financing led by Flagship Ventures and a consortium of private investors.\"<ref name=BioWorld_2013 />\n\n==CANbridge==\nIn September 2013 China's [[CANbridge]], which is commercializing Western clinical stage pharmaceutical products in China, appointed Termeer as Chief Advisor of their Life Sciences Advisory Board.<ref name=\"CANbridge\">{{citation |url=https://www.bio.org/canbridge-life-sciences-appoints-former-genzyme-ceo-henri-termeer-advisory-board |title=CANbridge Life Sciences Appoints Former Genzyme CEO, Henri Termeer, to Advisory Board |date=26 September 2013 |accessdate=8 July 2015 |location=Beijing |publisher=Business Wire }}{{Dead link|date=November 2018 |bot=InternetArchiveBot |fix-attempted=yes }}</ref>\n\n==Mentorship==\nIn 2015, from his home office in Marblehead, Massachusetts overlooking [[Marblehead Harbor]], Termeer continues to mentor former Genzyme colleagues who are now CEOs of about two dozen smaller companies.<ref name=\"bostonglobe_2015\">{{citation |title=How Genzyme became a source of biotech executives |url=https://www.bostonglobe.com/business/2015/07/11/genzyme-family-tree-how-henri-termeer-spawned-network-genzyme-alums-leading-dozens-biotechs-from-cambridge-stockholm/Dkoz2zcLlNz3N6OZbOvN4L/story.html# |publisher=Boston Globe |date=12 July 2015 |accessdate=17 July 2015 |author=Robert Weisman}}</ref> Among this group of elite biotech entrepreneurs \u2014 the \"Genzyme diaspora\"\u2014  are Geoff McDonough, now CEO of [[Swedish Orphan Biovitrum AB]] of [[Stockholm]], Gail Maderis, who runs biotechnology firms and an industry trade group in the [[San Francisco Bay]] area, Tom Mathers, CEO at [[CoLucid Pharmaceuticals Inc]], Jeff Albers has a Cambridge-based startup, Blueprint Medicines Corporation and Greg Madison, CEO of New York's Keryx Biopharmaceuticals Inc.<ref name=\"bostonglobe_2015\" />\n\n==Awards==\n\n* 1990\u20131992 [[The Wall Street Transcript]] Gold Award\n* 1995 [[Success (magazine)|Success Magazine]]  'Renegade of the Year'\n* 1999 Golden Door award from the [[International Institute of New England]], an award that symbolizes the positive influence that immigrants have had on America.\n* 2003 Cor Vitae Award from the [[American Heart Association]]\n* In 2005 Genzyme received the [[National Medal of Technology and Innovation]], the highest honor awarded by the President of the United States for technological innovation. Termeer accepted the award on behalf of Genzyme \"For pioneering dramatic improvements in the health of thousands of patients with rare diseases and harnessing the promise of biotechnology to develop innovative new therapies.\"\n* 2007 [[Ernst & Young Entrepreneur of the Year Award]]\n* 2008 [[Biotechnology Heritage Award]], from the [[Biotechnology Industry Organization]] (BIO) and the [[Chemical Heritage Foundation]]<ref name=\"Biotechnology\">{{cite web|title=Biotechnology Heritage Award|url=https://www.sciencehistory.org/biotechnology-heritage-award|website=Science History Institute|accessdate=22 March 2018}}</ref><ref name=Krughoff>{{cite news|last=Krughoff|first=Tracy|title=Henri A. Termeer to Receive 2008 Biotechnology Heritage Award|url=http://www.bio.org/media/press-release/henri-termeer-receive-2008-biotechnology-heritage-award|accessdate=5 February 2014|publisher=BIO|date=15 June 2008}}</ref>\n\n===Global Genes RARE Project Champions of Hope===\n\nIn 2012 Termeer received the Lifetime Achievement Award  from Nicole Boice, founder and CEO, Global Genes R.A.R.E Project. He was honoured for leading Genzyme for nearly 30 years and helping \"to establish Massachusetts as a major center of industrial biotech research and development,\" for \"spearheading the development of rare disease treatments at a time when other pharmaceutical companies were focusing on drugs for much larger patient populations.\"<ref name=\"RARE\">{{citation |url=https://globalgenes.org/raredaily/global-genes-and-r-a-r-e-project-announce-tribute-to-champions-of-hope-gala-to-honor-rare-and-genetic-disease-pioneers-innovators-and-advocates/ |work=Global Genes |title=Global Genes and R.A.R.E. Project Announce Tribute to Champions of Hope\u2122 Gala to Honor Rare and Genetic Disease Pioneers, Innovators and Advocates |location=Dana Point, California|date=27 June 2012 |accessdate=9 July 2015}}</ref>\n\n==Academic==\n*1999 Fellow of the [[American Academy of Arts and Sciences]]\n* 1999 Genetic Disease Foundation Humanitarian Award\n* 2005 Honorary Fellowship at the British [[Royal College of Physicians]]\n\n==Other affiliations==\nTermeer is \"connected to 311 board members in 17 different organizations across 20 different industries\"<ref name=\"Bloomberg\" /> including [[AutoImmune]] Inc., [[Diacrin]], Inc., [[rEVO Biologics]], Inc., [[Allergan]] Inc., Genzyme Corporation, [[Tekla]] Life Sciences Investors, [[AVEO Pharmaceuticals]], Partners HealthCare System, [[Federal Reserve Bank of Boston]], [[Biotechnology Industry Organization]], [[Erasmus University]], [[Capital Royalty]], [[Federal Reserve Bank of Atlanta]], Colgate W. Darden Graduate School of Business Administration, [[Longwood Founders Management]], Verastem, [[Moderna Therapeutics]], [[ProQR Therapeutics]], [[CANbridge Life Sciences]] and the [[Fellows of Harvard Medical School]] Termeer serves on their board of directors.<ref name=\"Verastem_2015\" /><ref name=\"about-hms\">{{citation |url=https://hms.harvard.edu/about-hms/board-fellows |work=Fellows of Harvard Medical School |title=Board of Directors}}</ref>\n\n==Lysosomal Therapeutics==\n\nTermeer provided financial backing for Lysosomal Therapeutics or N.V.Lysosomal Therapeutics Inc., a fledgling biotech firm in Boston, developing a treatment for Parkinson's and other neurodegenerative diseases. According to Bloomberg Termeer is the founder of Lysosomal Therapeutics.<ref name=\"Bloomberg\" /> Termeer is mentoring Lysosomal Therapeutics CEO Dimitri Krainc, who is a neurologist at Massachusetts General Hospital and is originally from Slovenia. According to Krainc, he and Termeer are in \"contact by e-mail, phone, or in person weekly. ... \"It's fun to meet with Henri. He listens. He's got incredibly good judgment. And he's very focused on the patients.\"<ref name=\"Boston_Globe_2014\" />\n\n==Philanthropy==\n\n===Massachusetts General Hospital===\nTermeer $10 million donation.<ref name=\"McBride_2012\" /> funds research at the Henri and Belinda Termeer Center for Targeted Therapies at the [[Massachusetts General Hospital]] Cancer Center<ref name=\"McBride_2012\" /> where patients with early and advanced stage cancers enroll in \"its fast-growing portfolio of Phase I, Phase II and Phase III clinical trials.\"<ref name=\"MGH_2012\">{{citation |url=http://www.massgeneral.org/cancer/services/treatmentprograms.aspx?id=1544 |title=Treatment Programs |work=Massachusetts General Hospital}}</ref> Termeer is on the board of directors of the MGH and has served on numerous committees with Peter Slavin, Hospital director.<ref name=\"MGH_2012_opening\">{{citation |url=http://www.massgeneral.org/cancer/news/multimedia.aspx?id=629 |title=Termeer Center Opening Reception |date=2 October 2012 |accessdate=9 July 2015}}Talks by MGH President Dr. Peter Slavin, Mass General Cancer Center Director Dr. Daniel Haber, Termeer Center Director Dr. Keith Flaherty, patient John Murphy and donor Henri Termeer</ref>\n\nIn 2011 Termeer [[Cathy Minehan]], and [[Charles K. Gifford|Chad Gifford]]\u2014 fellow [[Partners HealthCare]] Board Members\u2014 co-chaired the Massachusetts General Hospital bicentennial. The gala, with 1,000 in attendance, also served as a fundraiser, raising approximately $1 million.<ref name=\"MGH_200\">{{citation |url=http://www.boston.com/2011/09/19/namesmgh/2Cxwc9DEpGQ3dfV407lzkI/story.html |title=Kissinger, Gifford, Termeer attend MGH bicentennial |date=19 September 2011 |publisher=Boston Globe |accessdate=16 July 2015}}</ref>\n\n==Popular culture==\nThe 2010 Hollywood film entitled [[Extraordinary Measures]] starring [[Harrison Ford]] as [[John Crowley (biotech executive)|John Crowley]]\n<ref name=\"NYT_Crowley\">{{citation |url=http://well.blogs.nytimes.com/2010/01/22/a-fathers-quest-to-cure-his-children/ |title=A Father's Quest to Cure His Children |author=Tara Parker-Pope |date=22 January 2010 |accessdate=14 July 2015 |work=New York Time blog}}</ref> working at Genzyme Corporation in Cambridge with Henri Termeer as CEO. It is allegedly based on the true story behind Genzyme's development of [[Myozyme]] for the treatment for Pompe disease, a rare enzyme deficiency. Boston Globe staffer Geeta Anand wrote a book on the topic called '''The Cure'''.<ref name=\"extraordinary_measures\">{{citation |title=Extraordinary Measures True Genzyme Story|date=16 January 2010 |accessdate=14 July 2014 |author=Jeffrey Newman |url=http://www.futurevigil.com/2010/01/film-extraordinary-measures-true-genzyme-story/ }}</ref>\n\nCrowley was profiled in ''[[The Wall Street Journal]]'' by [[Pulitzer Prize]]-winning journalist [[Geeta Anand]].<ref>[[Geeta Anand|Anand, Geeta]]. [https://www.wsj.com/articles/SB106184568337857300 \"For His Sick Kids, a Father Struggled to Develop a Cure\"]. ''[[The Wall Street Journal]]'', August 26, 2003. Accessed April 4, 2008.</ref>  Anand expanded the profile of Crowley into a book published in 2006, ''The Cure: How a Father Raised $100 Million&nbsp;\u2013 And Bucked the Medical Establishment&nbsp;\u2013 In a Quest to Save His Children'' ({{ISBN|978-0060734398}}).<ref>[http://magazine.nd.edu/news/9879-taking-matters-into-his-own-hands/ \"Taking Matters Into His Own Hands\"]. ''Notre Dame Magazine'', Spring 2007. Accessed November 28, 2011.</ref>\n\nHarrison Ford and Double Feature films optioned the rights to produce a film inspired by Anand's book and the Crowley family.<ref>[http://www.variety.com/article/VR1117987104.html?categoryid=13&cs=1 \"Crowley Lures Harrison Ford To CBS\"]. Variety.com, June 9, 2008. Accessed June 16, 2008.</ref> In April 2009, CBS Films began filming this major motion picture about the Crowley family's quest to save their children's lives. The film, titled ''[[Extraordinary Measures]]''<ref>{{cite web|url=https://us.imdb.com/title/tt1244659/|title=Extraordinary Measures|publisher=IMDb.com, Inc.|accessdate=2009-09-29}}</ref><ref>{{cite news|url=http://blogs.wweek.com/news/author/amesh/ |title=News and Culture: Brenden Fraser's Untitled Crowley Project Now Has (Another) Terrible Title |date=September 24, 2009 |work=[[Willamette Week]] |accessdate=2009-09-29 |url-status=dead |archiveurl=https://web.archive.org/web/20091023223408/http://blogs.wweek.com/news/author/amesh/ |archivedate=October 23, 2009 }}</ref> was released nationwide on January 22, 2010. Directed by [[Tom Vaughan (director)|Tom Vaughan]], ''Extraordinary Measures'' stars [[Brendan Fraser]] as John Crowley and [[Keri Russell]] as Aileen Crowley, and also executive producer [[Harrison Ford]] as \"Dr. Robert Stonehill\" who is a composite character based primarily on Dr. [[William Canfield]] and inspired as well by other doctors Crowley worked with.<ref>[http://www.genzyme.com/pompemovie/pompe-movie-faq.htm \"The Successful Effort to Develop Myozyme for Pompe Disease at Genzyme FAQs\"] {{webarchive |url=https://web.archive.org/web/20100125192214/http://www.genzyme.com/pompemovie/pompe-movie-faq.htm |date=January 25, 2010 }}</ref>\n\n==References==\n{{reflist}}\n\n\n{{authority control}}\n\n{{DEFAULTSORT:Termeer, Henri}}\n[[Category:1946 births]]\n[[Category:2017 deaths]]\n[[Category:University of Virginia alumni]]\n[[Category:American chief executives]]\n[[Category:Fellows of the American Academy of Arts and Sciences]]\n[[Category:People from Tilburg]]\n[[Category:Dutch emigrants to the United States]]\n[[Category:Erasmus University Rotterdam alumni]]\n", "name_user": "Rjwilmsi", "label": "safe", "comment": "Journal cites:,", "url_page": "//en.wikipedia.org/wiki/Henri_Termeer"}
{"title_page": "Michael Cranford", "text_new": "{{BLP sources|date=July 2012}}\n\n{{Infobox person\n| name        = Michael Cranford\n| image       = Michael_Cranford_2013.jpg\n| caption     = Michael Cranford, 2013\n| birth_date  = {{Birth date and age|1963|6|5}}\n| birth_place = [[Orange, California]], U.S.\n| residence   = [[San Clemente, California]], U.S.\n| alma_mater  = [[University of Southern California]]\n| employer    = [[Human Engineered Software]]<br>[[Atari, Inc.]]<br>[[Interplay]]<br>[[Broderbund]]<br>[[Cyberdreams]]\n| occupation  = [[Video game designer]], [[Video game programmer|programmer]], [[ethicist]], [[software architect]], [[writer]]\n| children    = 3\n}}\n'''Michael Cranford''' is a [[video game designer]], [[Video game programmer|programmer]], [[ethicist]], and [[software architect]].\n\n== Game designer ==\nCranford is best known as a video game designer and programmer. He was the designer and programmer of 1985's ''[[Bard's Tale (1985)|The Bard's Tale]]''<ref name=\"Tresca2010\">{{cite book|last=Tresca|first=Michael J.|title=The Evolution of Fantasy Role-Playing Games|url=https://books.google.com/books?id=8H8bzqj6S4sC&pg=PA139|accessdate=10 July 2012|date=2010-11-16|publisher=McFarland|isbn=9780786458950|pages=139\u2013}}</ref> and 1986's ''[[Bard's Tale II|The Bard's Tale II: The Destiny Knight]]'' [[role-playing video game]]s published by [[Interplay Productions]]. He also programmed the [[Apple II]] version of ''[[Donkey Kong (video game)|Donkey Kong]]'', the [[Commodore 64]] version of ''[[Super Zaxxon]]'', as well as ''Maze Master'' (a spiritual predecessor of ''The Bard's Tale''). His last video game was ''[[Dark Seed (video game)|Dark Seed]]'' for [[Cyberdreams]] in 1992. He left the [[video game industry]] to pursue graduate studies, and thus was not involved in the creation of 1988's ''[[Bard's Tale III|The Bard's Tale III]]''. Almost thirty years later, however, he was approached by [[inXile Entertainment]] to assist with the development of ''[[The Bard's Tale IV]]'' and had agreed to provide feedback and advice for the new game.<ref name=\"Bards_Tale_IV\">{{cite web|url=https://www.kickstarter.com/projects/inxile/the-bards-tale-iv/posts/1901203|title=Update 37: Bringing an Iconic Series into the 21st Century|author=[[inXile Entertainment]]|first=16 June 2017|work=[[Kickstarter]]|accessdate=17 June 2017}}</ref>\n\n===Games===\n{| class=\"wikitable sortable\" border=\"1\"\n|-\n! scope=\"col\" | Name\n! scope=\"col\" | Year\n! scope=\"col\" | Credited with\n! scope=\"col\" | Publisher\n|-\n| ''Story Machine'' (VIC-20 port)  || [[1983 in video gaming|1983]] || programmer || [[Human Engineered Software]]\n|-\n| ''Maze Master''  || [[1983 in video gaming|1983]] || designer || Human Engineered Software\n|-\n| ''[[Super Zaxxon]]'' (C64 port)  || [[1984 in video gaming|1984]] || programmer || Human Engineered Software\n|-\n| ''[[Donkey Kong (video game)|Donkey Kong]]'' (Apple II port)  || [[1984 in video gaming|1984]] || programmer || [[Atarisoft]]\n|-\n| ''[[The Bard's Tale (1985 video game)|The Bard's Tale]]'' || [[1985 in video gaming|1985]] || designer, programmer || [[Electronic Arts]]\n|-\n| ''[[Borrowed Time (video game)|Borrowed Time]]'' || [[1985 in video gaming|1985]] || writer || [[Activision]]\n|-\n| ''[[The Bard's Tale II: The Destiny Knight]]'' || [[1986 in video gaming|1986]] || designer || Electronic Arts\n|-\n| ''Centauri Alliance'' || [[1990 in video gaming|1990]] || designer, programmer || [[Broderbund]]\n|-\n| ''[[Dark Seed (video game)|Dark Seed]]'' || [[1992 in video gaming|1992]] || designer || [[Cinemaware]]\n|}\n\n== Academic career ==\nHe was a professor for eight years at [[Biola University]] in [[La Mirada, California]], gaining his Master of Divinity degree from Biola and a [[master's degree]] in Social Ethics from the [[University of Southern California]]. He studied architecture at the [[University of California at Berkeley]] and he holds a degree in [[philosophy]] from the [[University of California]], and has completed a Ph.D. in [[Religion and Social Ethics]] from the University of Southern California, with a focus on ethics and technology. His current work focuses on web application development and voice-interactive interfaces.\n\n== Publications ==\n* {{cite journal|last=Cranford|first=Michael|title=Election and Ethnicity: Paul's View of Israel in Romans 9.1-13|journal=Journal for the Study of the New Testament|issue=50|publisher=University of Sheffield|location=England|year=1993|pages=27\u201341}}\n* {{cite journal|last=Cranford|first=Michael|title=The Possibility of Perfect Obedience: Paul and an Implied Premise in Galatians 3:10 and 5:3|journal=Novum Testamentum|issue=36|publisher=E.J. Brill Publishers|location=Netherlands|year=1994|pages=242\u2013258}}\n* {{cite journal|last=Cranford|first=Michael|title=Abraham in Romans 4: The Father of All Who Believe|journal=New Testament Studies|issue=41|publisher=Cambridge University Press|year=1995|pages=71\u201388}}\n* {{cite journal|last=Cranford|first=Michael|title=The Social Trajectory of Virtual Reality: Substantive Ethics in a World Without Constraints|journal=Technology in Society|issue=18|year=1996|pages=79\u201392}}\n* {{cite journal|last=Cranford|first=Michael|title=Drug Testing and the Right to Privacy: Arguing the Ethics of Workplace Drug Testing|journal=Journal of Business Ethics|issue=17|date=December 1998|pages=1805\u20131815}} Reprinted in {{cite book|editor=Beauchamp & Bowie|title=Ethical Theory and Business|edition=6th & 7th|year=2001|publisher=Prentice Hall|location=New Jersey|pages=294\u2013302}}\n* {{cite journal|last=Cranford|first=Michael|title=Drug Testing and the Obligation to Prevent Harm|journal=Business Ethics: Decision-Making for Personal Integrity and Social Responsibility|publisher=McGraw Hill|location=Boston|year=2007|editors=Laura P. Hartman and Joe DesJardines|pages=301\u2013307}}\n\n==Personal life==\nCranford is a Christian with no denominational affiliation. He was divorced in October 2013, though he refused to participate in the divorce due to his religious convictions. He has three children from the marriage: Logan, Leilani and Dylan.\n\n==References==\n{{Reflist}}\n\n==External links==\n*{{moby developer|id=11314|name=Michael Cranford's profile}}\n*[http://bardstale.poverellomedia.com/about.html The Bard's Tale Compendium] - more information about Michael Cranford's popular game series\n*[https://www.gamasutra.com/view/news/310470/GDC_2018_will_host_a_Classic_Game_Postmortem_of_The_Bards_Tale.php GDC 2018 will host a Classic Game Postmortem of The Bard's Tale!] - Cranford's upcoming lecture at the 2018 Game Developer's Conference\n\n{{Bard's Tale series}}\n\n{{authority control}}\n\n{{DEFAULTSORT:Cranford, Michael}}\n[[Category:1963 births]]\n[[Category:American ethicists]]\n[[Category:American video game designers]]\n[[Category:American video game programmers]]\n[[Category:Biola University alumni]]\n[[Category:Biola University faculty]]\n[[Category:Interplay Entertainment people]]\n[[Category:Living people]]\n[[Category:People from Orange, California]]\n[[Category:People from San Clemente, California]]\n[[Category:UC Berkeley College of Environmental Design alumni]]\n[[Category:University of Southern California alumni]]\n", "text_old": "{{BLP sources|date=July 2012}}\n\n{{Infobox person\n| name        = Michael Cranford\n| image       = Michael_Cranford_2013.jpg\n| caption     = Michael Cranford, 2013\n| birth_date  = {{Birth date and age|1963|6|5}}\n| birth_place = [[Orange, California]], U.S.\n| residence   = [[San Clemente, California]], U.S.\n| alma_mater  = [[University of Southern California]]\n| employer    = [[Human Engineered Software]]<br>[[Atari, Inc.]]<br>[[Interplay]]<br>[[Broderbund]]<br>[[Cyberdreams]]\n| occupation  = [[Video game designer]], [[Video game programmer|programmer]], [[ethicist]], [[software architect]], [[writer]]\n| children    = 3\n}}\n'''Michael Cranford''' is a [[video game designer]], [[Video game programmer|programmer]], [[ethicist]], and [[software architect]].\n\n== Game designer ==\nCranford is best known as a video game designer and programmer. He was the designer and programmer of 1985's ''[[Bard's Tale (1985)|The Bard's Tale]]''<ref name=\"Tresca2010\">{{cite book|last=Tresca|first=Michael J.|title=The Evolution of Fantasy Role-Playing Games|url=https://books.google.com/books?id=8H8bzqj6S4sC&pg=PA139|accessdate=10 July 2012|date=2010-11-16|publisher=McFarland|isbn=9780786458950|pages=139\u2013}}</ref> and 1986's ''[[Bard's Tale II|The Bard's Tale II: The Destiny Knight]]'' [[role-playing video game]]s published by [[Interplay Productions]]. He also programmed the [[Apple Computer|Apple]] version of ''[[Donkey Kong (video game)|Donkey Kong]]'', the [[Commodore 64]] version of ''[[Super Zaxxon]]'', as well as ''[[Maze Master]]'' (a spiritual predecessor of ''The Bard's Tale''). His last video game was ''[[Dark Seed (video game)|Dark Seed]]'' for [[Cyberdreams]] in 1992. He left the [[video game industry]] to pursue graduate studies, and thus was not involved in the creation of 1988's ''[[Bard's Tale III|The Bard's Tale III]]''. Almost thirty years later, however, he was approached by [[inXile Entertainment]] to assist with the development of ''[[The Bard's Tale IV]]'' and had agreed to provide feedback and advice for the new game.<ref name=\"Bards_Tale_IV\">{{cite web|url=https://www.kickstarter.com/projects/inxile/the-bards-tale-iv/posts/1901203|title=Update 37: Bringing an Iconic Series into the 21st Century|author=[[inXile Entertainment]]|first=16 June 2017|work=[[Kickstarter]]|accessdate=17 June 2017}}</ref>\n\n===Games===\n{| class=\"wikitable sortable\" border=\"1\"\n|-\n! scope=\"col\" | Name\n! scope=\"col\" | Year\n! scope=\"col\" | Credited with\n! scope=\"col\" | Publisher\n|-\n| ''Story Machine'' (VIC-20 port)  || [[1983 in video gaming|1983]] || programmer || [[Human Engineered Software]]\n|-\n| ''Maze Master''  || [[1983 in video gaming|1983]] || designer || Human Engineered Software\n|-\n| ''[[Super Zaxxon]]'' (C64 port)  || [[1984 in video gaming|1984]] || programmer || Human Engineered Software\n|-\n| ''[[Donkey Kong (video game)|Donkey Kong]]'' (Apple II port)  || [[1984 in video gaming|1984]] || programmer || [[Atarisoft]]\n|-\n| ''[[The Bard's Tale (1985 video game)|The Bard's Tale]]'' || [[1985 in video gaming|1985]] || designer, programmer || [[Electronic Arts]]\n|-\n| ''[[Borrowed Time (video game)|Borrowed Time]]'' || [[1985 in video gaming|1985]] || writer || [[Activision]]\n|-\n| ''[[The Bard's Tale II: The Destiny Knight]]'' || [[1986 in video gaming|1986]] || designer || Electronic Arts\n|-\n| ''Centauri Alliance'' || [[1990 in video gaming|1990]] || designer, programmer || [[Broderbund]]\n|-\n| ''[[Dark Seed (video game)|Dark Seed]]'' || [[1992 in video gaming|1992]] || designer || [[Cinemaware]]\n|}\n\n== Academic career ==\nHe was a professor for eight years at [[Biola University]] in [[La Mirada, California]], gaining his Master of Divinity degree from Biola and a [[master's degree]] in Social Ethics from the [[University of Southern California]]. He studied architecture at the [[University of California at Berkeley]] and he holds a degree in [[philosophy]] from the [[University of California]], and has completed a Ph.D. in [[Religion and Social Ethics]] from the University of Southern California, with a focus on ethics and technology. His current work focuses on web application development and voice-interactive interfaces.\n\n== Publications ==\n* {{cite journal|last=Cranford|first=Michael|title=Election and Ethnicity: Paul's View of Israel in Romans 9.1-13|journal=Journal for the Study of the New Testament|issue=50|publisher=University of Sheffield|location=England|year=1993|pages=27\u201341}}\n* {{cite journal|last=Cranford|first=Michael|title=The Possibility of Perfect Obedience: Paul and an Implied Premise in Galatians 3:10 and 5:3|journal=Novum Testamentum|issue=36|publisher=E.J. Brill Publishers|location=Netherlands|year=1994|pages=242\u2013258}}\n* {{cite journal|last=Cranford|first=Michael|title=Abraham in Romans 4: The Father of All Who Believe|journal=New Testament Studies|issue=41|publisher=Cambridge University Press|year=1995|pages=71\u201388}}\n* {{cite journal|last=Cranford|first=Michael|title=The Social Trajectory of Virtual Reality: Substantive Ethics in a World Without Constraints|journal=Technology in Society|issue=18|year=1996|pages=79\u201392}}\n* {{cite journal|last=Cranford|first=Michael|title=Drug Testing and the Right to Privacy: Arguing the Ethics of Workplace Drug Testing|journal=Journal of Business Ethics|issue=17|date=December 1998|pages=1805\u20131815}} Reprinted in {{cite book|editor=Beauchamp & Bowie|title=Ethical Theory and Business|edition=6th & 7th|year=2001|publisher=Prentice Hall|location=New Jersey|pages=294\u2013302}}\n* {{cite journal|last=Cranford|first=Michael|title=Drug Testing and the Obligation to Prevent Harm|journal=Business Ethics: Decision-Making for Personal Integrity and Social Responsibility|publisher=McGraw Hill|location=Boston|year=2007|editors=Laura P. Hartman and Joe DesJardines|pages=301\u2013307}}\n\n==Personal life==\nCranford is a Christian with no denominational affiliation. He was divorced in October 2013, though he refused to participate in the divorce due to his religious convictions. He has three children from the marriage: Logan, Leilani and Dylan.\n\n==References==\n{{Reflist}}\n\n==External links==\n*{{moby developer|id=11314|name=Michael Cranford's profile}}\n*[http://bardstale.poverellomedia.com/about.html The Bard's Tale Compendium] - more information about Michael Cranford's popular game series\n*[https://www.gamasutra.com/view/news/310470/GDC_2018_will_host_a_Classic_Game_Postmortem_of_The_Bards_Tale.php GDC 2018 will host a Classic Game Postmortem of The Bard's Tale!] - Cranford's upcoming lecture at the 2018 Game Developer's Conference\n\n{{Bard's Tale series}}\n\n{{authority control}}\n\n{{DEFAULTSORT:Cranford, Michael}}\n[[Category:1963 births]]\n[[Category:American ethicists]]\n[[Category:American video game designers]]\n[[Category:American video game programmers]]\n[[Category:Biola University alumni]]\n[[Category:Biola University faculty]]\n[[Category:Interplay Entertainment people]]\n[[Category:Living people]]\n[[Category:People from Orange, California]]\n[[Category:People from San Clemente, California]]\n[[Category:UC Berkeley College of Environmental Design alumni]]\n[[Category:University of Southern California alumni]]\n", "name_user": "Mika1h", "label": "safe", "comment": "\u2192\u200eGame designer", "url_page": "//en.wikipedia.org/wiki/Michael_Cranford"}
{"title_page": "2016 Scottish Cup Final", "text_new": "{{Use dmy dates|date=May 2016}}\n{{Infobox football match\n| title              = 2016 Scottish Cup Final\n| image              = 2016 Scottish Cup Final.jpg\n| image_size         = 200\n| caption            = Official programme cover\n| event              = [[2015\u201316 Scottish Cup]]\n| team1              = [[Rangers F.C.|Rangers]]\n| team1score         = 2\n| team2              = [[Hibernian F.C.|Hibernian]]\n| team2score         = 3\n| date               = 21 May 2016\n| stadium            = [[Hampden Park]]\n| city               = [[Glasgow]]\n| man_of_the_match1a = [[Anthony Stokes]] (Hibernian)\n| referee            = [[Steven McLean (referee)|Steven McLean]]\n| attendance         = 50,701\n| previous           = [[2015 Scottish Cup Final|2015]]\n| next               = [[2017 Scottish Cup Final|2017]]\n}}\nThe '''2016 Scottish Cup Final''' was the 131st final of the [[Scottish Cup]] and the final of the [[2015\u201316 Scottish Cup]], the most prestigious knockout [[association football|football]] competition in Scotland. The match took place at [[Hampden Park]] on 21 May 2016 and was contested by [[Scottish Championship]] teams [[Rangers F.C.|Rangers]] and [[Hibernian F.C.|Hibernian]].<ref name=rangers>{{cite web|url=https://www.bbc.co.uk/sport/football/36008631 |title=Scottish Cup semi-final: Rangers 2\u20132 Celtic (5\u20134 pens) |publisher=BBC Sport |date=17 April 2016 |accessdate=17 April 2016}}</ref> It was the first final to be contested by two teams from outside the top tier of the [[Scottish football league system]].<ref name=rangers /> Hibernian ended a run of 114 years from last winning the competition, beating Rangers 3-2 with a stoppage time goal from [[captain (association football)|club captain]] [[David Gray (footballer, born 1988)|David Gray]].<ref>{{cite news|url=https://www.bbc.co.uk/sport/football/36292302|title=Scottish Cup final: Rangers 2\u20133 Hibernian |publisher=BBC Sport |date=21 May 2016 |accessdate=21 May 2016}}</ref>\n\nThe winners, Hibernian, entered the second qualifying round of the [[2016\u201317 UEFA Europa League]].<ref>{{cite web|author=UEFA Europa League |url=http://www.uefa.com/uefaeuropaleague/season=2017/accesslist/index.html |title=2016/17 UEFA Europa League access list  |publisher=UEFA |date= |accessdate=17 April 2016}}</ref>\n\n== Route to the final ==\n===Hibernian===\nHibernian started the Scottish Cup in the fourth round as one of the top four placed teams in the [[2014\u201315 Scottish Championship]]. They were drawn away at fellow Championship team [[Raith Rovers F.C.|Raith Rovers]]. At [[Stark's Park]], Hibernian won 2\u20130 with goals from [[Darren McGregor]] and [[Dominique Malonga]].<ref name=rai>{{cite web|url=https://www.bbc.co.uk/sport/football/35211876 |title=Raith Rovers 0\u20132 Hibernian |publisher=BBC Sport |date=9 January 2016 |accessdate=17 April 2016}}</ref> In the fifth round, they were drawn away against their [[Edinburgh derby]] rivals and [[Scottish Premiership|Premiership]] club, [[Heart of Midlothian F.C.|Heart of Midlothian]]. Following a 2\u20132 draw at [[Tynecastle Stadium]], Hibernian won the replay at their [[Easter Road]] 1\u20130 via a [[Jason Cummings]] goal.<ref name=hom>{{cite web|url=https://www.bbc.co.uk/sport/football/35535920 |title=Hibernian 1\u20130 Heart of Midlothian |publisher=BBC Sport |date=16 February 2016 |accessdate=17 April 2016}}</ref> In the quarter finals they were drawn at home against the Scottish Cup holders, Premiership side [[Inverness Caledonian Thistle F.C.|Inverness Caledonian Thistle]]. Following a 1\u20131 draw, Hibernian won the replay at [[Caledonian Stadium]] 2\u20131 due to two goals from [[Anthony Stokes]].<ref name=ict>{{cite web|url=https://www.bbc.co.uk/sport/football/35760970 |title=Scottish Cup: Inverness CT 1\u20132 Hibernian |publisher=BBC Sport |date=16 March 2016 |accessdate=17 April 2016}}</ref> In the semi-final at neutral Hampden Park, they were drawn against Premiership [[Dundee United F.C.|Dundee United]] and progressed to the final after winning 4\u20132 in a [[penalty shoot out]].<ref name=duu>{{cite web|url=https://www.bbc.co.uk/sport/football/36003988 |title=Scottish Cup semi-final: Hibernian 0\u20130 Dundee United (Hibs win 4\u20132 on penalties) |publisher=BBC Sport |date=16 April 2016 |accessdate=17 April 2016}}</ref>\n\n{| class=\"wikitable\" style=\"text-align:left;margin-left:1em;float:right\"\n|-\n!width=125|Round\n!width=110|Opposition\n!width=110|Location\n!width=80|Score\n|-\n!colspan=4|Rangers\n|-\n | [[2015\u201316 Scottish Cup#Fourth round|Fourth round]]\n | [[Cowdenbeath F.C.|Cowdenbeath]]\n | [[Ibrox Stadium|Ibrox]]\n | align=center|5\u20131<ref name=cow />\n|-\n | [[2015\u201316 Scottish Cup#Fifth round|Fifth round]]\n | rowspan=2|[[Kilmarnock F.C.|Kilmarnock]]\n | [[Ibrox Stadium|Ibrox]]\n | align=center|0\u20130<ref name=kil />\n|-\n | [[2015\u201316 Scottish Cup#Replays 5|Fifth round replay]]\n | [[Rugby Park]]\n | align=center|2\u20131<ref name=cow />\n|-\n | [[2015\u201316 Scottish Cup#Quarter-finals|Quarter-final]]\n | [[Dundee F.C.|Dundee]]\n | [[Ibrox Stadium|Ibrox]]\n | align=center|4\u20130<ref name=dun />\n|-\n | [[2015\u201316 Scottish Cup#Semi-finals|Semi-final]]\n | [[Celtic F.C.|Celtic]]\n | [[Hampden Park]]\n | align=center|2\u20132 ([[Extra time|a.e.t.]])<br>(5\u20134 [[Penalty shootout (association football)|pen.]])<ref name=rangers />\n|-\n !colspan=4|Hibernian\n|-\n | [[2015\u201316 Scottish Cup#Fourth round|Fourth round]]\n | [[Raith Rovers F.C.|Raith Rovers]]\n | [[Stark's Park]]\n | align=center|2\u20130<ref name=rai />\n|-\n | [[2015\u201316 Scottish Cup#Fifth round|Fifth round]]\n | rowspan=2|[[Heart of Midlothian F.C.|Hearts]]\n | [[Tynecastle Stadium|Tynecastle]]\n | align=center|2\u20132<ref name=hom />\n|-\n | [[2015\u201316 Scottish Cup#Replays 5|Fifth round replay]]\n | [[Easter Road]]\n | align=center|1\u20130<ref name=hom />\n|-\n | [[2015\u201316 Scottish Cup#Quarter-finals|Quarter-final]]\n | rowspan=2|[[Inverness Caledonian Thistle F.C.|Inverness Caledonian Thistle]]\n | [[Easter Road]]\n | align=center|1\u20131<ref name=ict />\n|-\n | [[2015\u201316 Scottish Cup#Replays 6|Quarter-final replay]]\n | [[Caledonian Stadium]]\n | align=center|2\u20131<ref name=ict />\n|-\n | [[2015\u201316 Scottish Cup#Semi-finals|Semi-final]]\n | [[Dundee United F.C.|Dundee United]]\n | [[Hampden Park]]\n | align=center|0\u20130 ([[Extra time|a.e.t.]])<br>(4\u20132 [[Penalty shootout (association football)|pen.]])<ref name=duu />\n|}\n\n===Rangers===\nRangers also started the Scottish Cup in the fourth round as one of the top four placed teams in the previous years Scottish Championship. In the fourth round they were drawn against [[Scottish League One]] team [[Cowdenbeath F.C.|Cowdenbeath]] at home. At their [[Ibrox Stadium]], Rangers won 5\u20131 with goals from [[Lee Wallace]], [[Barrie McKay]] and a [[hat-trick]] from [[Martyn Waghorn]].<ref name=cow>{{cite web|url=https://www.bbc.co.uk/sport/football/35216463 |title=Scottish Cup fourth round: Rangers 5\u20131 Cowdenbeath |publisher=BBC Sport |date=10 January 2016 |accessdate=17 April 2016}}</ref> In the next round they were drawn with Premiership team [[Kilmarnock F.C.|Kilmarnock]]. After a 0\u20130 draw at Ibrox Stadium, Rangers won 2\u20131 in the replay at [[Rugby Park]] with goals from Waghorn and [[Nicky Clark]].<ref name=kil>{{cite web|url=https://www.bbc.co.uk/sport/football/35535921 |title=Scottish Cup: Kilmarnock 1\u20132 Rangers |publisher=BBC Sport |date=16 February 2016 |accessdate=17 April 2016}}</ref> In the quarter finals, Rangers were drawn at home against Premiership [[Dundee F.C.|Dundee]], which they won 4\u20130 with goals from [[Harry Forrester (footballer)|Harry Forrester]], [[Jason Holt]], [[Andy Halliday]] and Wallace.<ref name=dun>{{cite web|url=https://www.bbc.co.uk/sport/football/35675919 |title=Scottish Cup: Rangers 4\u20130 Dundee |publisher=BBC Sport |date=5 March 2016 |accessdate=17 April 2016}}</ref> In the semi-finals, Rangers were drawn against their [[Old Firm]] rivals [[Celtic F.C.|Celtic]] in only their second derby since 2015.  Rangers progressed to the final winning 5\u20134 on penalties.<ref name=rangers /> Rangers entered the final as Scottish Championship league champions and [[Scottish Challenge Cup]] winners.<ref>{{cite web|last=Newport |first=Andy |url=http://www.belfasttelegraph.co.uk/sport/football/scottish/rangers/rangers-have-a-double-reason-to-celebrate-34615149.html |title=Rangers have a double reason to celebrate |publisher=Belfast Telegraph |date= |accessdate=17 April 2016}}</ref>\n\n==Pre-match==\nThis was Hibernian's 1st victory in the [[Scottish Cup Final]] in 114 years, having previously won two Scottish Cups (in [[1887 Scottish Cup Final|1887]] and [[1902 Scottish Cup Final|1902]]) and lost in ten finals since their last victory. The 2016 final marked their third appearance in the final in the space of five years, having lost to [[Heart of Midlothian F.C.|Hearts]] in [[2012 Scottish Cup Final|2012]] and [[Celtic F.C.|Celtic]] in [[2013 Scottish Cup Final|2013]]. Rangers appeared in the Scottish Cup final after winning the competition 33 times. The most recent appearance and victory for the club was in [[2009 Scottish Cup Final|2009]], when they defeated [[Falkirk F.C.|Falkirk]] 1\u20130. This was the first meeting of the clubs in the Scottish Cup since [[2007\u201308 Scottish Cup|2008]], when Rangers won 1\u20130 at [[Ibrox Stadium|Ibrox]] in a replay after a goalless draw at [[Easter Road]]. Hibernian and Rangers had previously met in one Scottish Cup Final, in [[1979 Scottish Cup Final|1979]]. Rangers won the cup that year by winning a second replay by 3\u20132, after the first two matches both finished goalless.<ref>{{cite web |url=http://www.rsssf.com/tabless/scotcuphistfull.html#79 |title=1978/79 |work=RSSSF |date= |accessdate=21 April 2016}}</ref>\n\n==Match==\n===Details===\n{{football box |\n |date = 21 May 2016\n |time = 15:00\n |team1 = [[Rangers F.C.|Rangers]]\n |score = 2\u20133\n |report = [https://www.bbc.com/sport/football/36292302 Report]\n |team2 = [[Hibernian F.C.|Hibernian]]\n |goals1 = [[Kenny Miller|Miller]] {{goal|27}}<br>[[Andy Halliday|Halliday]] {{goal|64}}\n |goals2 = [[Anthony Stokes|Stokes]] {{goal|3||80}}<br>[[David Gray (footballer, born 1988)|Gray]] {{goal|90+2}}\n |stadium = [[Hampden Park]], [[Glasgow]]\n |attendance = 50,701\n |referee = [[Steven McLean (referee)|Steven McLean]]\n}}\n\n{| width=92% |\n|{{Football kit\n|pattern_la=_whiteshoulders\n|pattern_b=_whiteshoulders\n|pattern_ra=_whiteshoulders\n|pattern_sh=_blue stripes\n|pattern_so=_redtop\n|leftarm=0000FF\n|body=0000FF\n|rightarm=0000FF\n|shorts=FFFFFF\n|socks=000000\n| title           = Rangers}}\n|{{Football kit\n| pattern_la = _thinborderonwhite\n| pattern_b  = _whitecollarplain\n| pattern_ra = _thinborderonwhite\n| pattern_sh =\n| pattern_so =\n| leftarm      = 003300\n| body         = 003300\n| rightarm     = 003300\n| shorts       = FFFFFF\n| socks        = FFFFFF\n| title           = Hibernian}}\n|}\n\n{| style=\"width:100%;\"\n|-\n|  style=\"vertical-align:top; width:50%;\"|\n{| style=\"font-size: 90%\" cellspacing=\"0\" cellpadding=\"0\"\n|-\n!width=\"25\"| !!width=\"25\"|\n|-\n|GK ||'''25''' || {{flagicon|ENG}} [[Wes Foderingham]]\n|-\n|DF ||'''2''' || {{flagicon|ENG}} [[James Tavernier]] || {{yel|56}}\n|-\n|DF ||'''4''' || {{flagicon|IRL}} [[Rob Kiernan]]\n|-\n|DF ||'''27''' || {{flagicon|SCO}} [[Danny Wilson (footballer, born 1991)|Danny Wilson]]\n|-\n|DF ||'''5''' || {{flagicon|SCO}} [[Lee Wallace]]\n|-\n|MF ||'''8''' || {{flagicon|USA}} [[Gedion Zelalem]] || || {{suboff|63}}\n|-\n|MF ||'''16''' || {{flagicon|SCO}} [[Andy Halliday]]\n|-\n|MF ||'''23''' || {{flagicon|SCO}} [[Jason Holt]]\n|-\n|MF ||'''19''' || {{flagicon|SCO}} [[Barrie McKay]]\n|-\n|FW ||'''33''' || {{flagicon|ENG}} [[Martyn Waghorn]] || || {{suboff|75}}\n|-\n|FW ||'''9''' || {{flagicon|SCO}} [[Kenny Miller]]\n|-\n|colspan=4|'''Substitutes:'''\n|-\n|GK ||'''1''' || {{flagicon|SCO}} [[Cammy Bell]]\n|-\n|MF ||'''7''' || {{flagicon|ENG}} [[Nicky Law (footballer, born 1988)|Nicky Law]]\n|-\n|MF ||'''14''' || {{flagicon|SCO}} [[Nicky Clark]] || || {{subon|75}}\n|-\n|MF ||'''22''' || {{flagicon|NIR}} [[Dean Shiels]] || || {{subon|63}}\n|-\n|MF ||'''62''' || {{flagicon|SCO}} [[Liam Burt]]\n|-\n\n|colspan=4|'''Manager:'''\n|-\n|colspan=\"4\"|{{flagicon|ENG}} [[Mark Warburton]]\n|}\n|valign=\"top\"|\n|  style=\"vertical-align:top; width:50%;\"|\n{| cellspacing=\"0\" cellpadding=\"0\" style=\"font-size:90%; margin:auto;\"\n|-\n!width=\"25\"| !!width=\"25\"|\n|-\n|GK ||'''25''' || {{flagicon|IRL}} [[Conrad Logan]]\n|-\n|DF ||'''2''' || {{flagicon|SCO}} [[David Gray (footballer, born 1988)|David Gray]]\n|-\n|DF ||'''24''' || {{flagicon|SCO}} [[Darren McGregor]]\n|-\n|DF ||'''4''' || {{flagicon|SCO}} [[Paul Hanlon]] || || {{suboff|83}}\n|-\n|DF ||'''5''' || {{flagicon|ENG}} [[Liam Fontaine]] || || {{suboff|70}}\n|-\n|DF ||'''16''' || {{flagicon|SCO}} [[Lewis Stevenson (Scottish footballer)|Lewis Stevenson]]\n|-\n|MF ||'''8''' || {{flagicon|SCO}} [[Fraser Fyvie]] || {{yel|59}}\n|-\n|MF ||'''10''' || {{flagicon|SCO}} [[Dylan McGeouch]]\n|-\n|MF ||'''18''' || {{flagicon|SCO}} [[John McGinn]]\n|-\n|FW ||'''28''' || {{flagicon|IRL}} [[Anthony Stokes]]\n|-\n|FW ||'''35''' || {{flagicon|SCO}} [[Jason Cummings]] || || {{suboff|65}}\n|-\n|colspan=4|'''Substitutes:'''\n|-\n|GK ||'''1''' || {{flagicon|ENG}} [[Mark Oxley]]\n|-\n|MF ||'''3''' || {{flagicon|SCO}} [[Liam Henderson (footballer, born 1996)|Liam Henderson]] || || {{subon|70}}\n|-\n|MF ||'''6''' || {{flagicon|ENG}} [[Marvin Bartley]]\n|-\n|MF ||'''17''' || {{flagicon|AUS}} [[Martin Boyle]]\n|-\n|FW ||'''19''' || {{flagicon|SCO}} [[James Keatings]] || || {{subon|65}}\n|-\n|DF ||'''27''' || {{flagicon|NOR}} [[Niklas Gunnarsson]] || || {{subon|83}}\n|-\n|FW ||'''29''' || {{flagicon|ENG}} [[Chris Dagnall]]\n|-\n|colspan=4|'''Manager:'''\n|-\n|colspan=\"4\"|{{flagicon|ENG}} [[Alan Stubbs]]\n|}\n|}\n\n'''Match rules'''\n* 90 minutes\n* 30 minutes of extra time if necessary\n* Penalty shoot-out if scores still level\n* Seven named substitutes\n* Maximum of three substitutions\n\n==Post-match==\nAt the end of the match, thousands of Hibernian fans spilled out onto the pitch and were met by groups of Rangers fans leading to fights occurring.<ref>{{Cite web|url=https://www.theguardian.com/football/2016/may/21/rangers-hibernian-scottish-cup-final-match-report|title= Hibernian and David Gray stun Rangers to make Scottish Cup history|date=21 May 2016|work=Guardian|accessdate=24 May 2016}}</ref> Rangers claimed that some of their players and staff had been assaulted by the Hibernian fans as they tried to leave the pitch, however no evidence was shown to suggest this was the case. <ref>{{Cite web|url=https://www.telegraph.co.uk/football/2016/05/21/fights-on-pitch-mar-hibernians-scottish-cup-victory-over-rangers/|title= Rangers 2 Hibernian 3: Post-match violence mars Hibs' astonishing last-gasp victory|date=21 May 2016|work=Daily Telegraph|accessdate=24 May 2016}}</ref> The Rangers team received their runners-up medals in the dressing room. The [[Scottish Football Association|SFA]] conducted a full investigation into the crowd trouble.<ref>{{Cite web|url=https://www.bbc.com/news/uk-scotland-glasgow-west-36350220|title= Scottish Cup final: Disorder after Hibs win 'appalling'|date=21 May 2016|work=BBC Sport|accessdate=24 May 2016}}</ref> The report was published in August and found that neither club was to blame but that the invasion was caused by the Hibs supporters' exuberance at winning the cup. It was pointed out that Rangers supporters had let off fireworks and sung sectarian songs during the match. The report suggested the possibility of making pitch invasions illegal as they are in England.<ref>{{cite news|url=https://www.bbc.co.uk/news/uk-scotland-scotland-politics-36991311|title=Scottish Cup Final report: Consider making pitch invasions illegal - BBC News|date=5 August 2016|work=[[BBC Online]]|accessdate=28 October 2016}}</ref><ref>{{cite web|url=http://www.scottishfa.co.uk/resources/documents/Documents/ScottishCupFinal2016Report/Scottish%20Cup%20Final%202016%20Commission%20of%20Enquiry%20-%20Report%20of%20SP%20Bowen.pdf|title=Scottish Cup Final 2016 Commission of Enquiry - Report of SP Bowen|accessdate=28 October 2016|archive-url=https://web.archive.org/web/20161029113409/http://www.scottishfa.co.uk/resources/documents/Documents/ScottishCupFinal2016Report/Scottish%20Cup%20Final%202016%20Commission%20of%20Enquiry%20-%20Report%20of%20SP%20Bowen.pdf|archive-date=29 October 2016|url-status=dead|df=dmy-all}}</ref> The aftermath of the final is also notable for the five-minute rendition by Hibs' fans, having returned to the stands, of the club's  anthem, the [[The Proclaimers|Proclaimers']] \"[[Sunshine on Leith (song)|Sunshine on Leith]]\".<ref>{{Cite web|url=https://www.tifofootball.com/features/how-hibernians-sunshine-on-leith-became-an-anthem-for-all-of-football |title= How Hibernian\u2019s Sunshine On Leith became an anthem for all of football\n |date=23 March 2018 |work= Tifo | author= Stephen Tudor | accessdate=23 April 2019}}</ref>\n\n== References ==\n{{reflist|30em}}\n\n{{Scottish Cup seasons}}\n{{2015\u201316 in Scottish football}}\n{{Hibernian F.C. matches}}\n{{Rangers F.C. matches}}\n\n[[Category:Scottish Cup Finals]]\n[[Category:Rangers F.C. matches|Scottish Cup Final 2016]]\n[[Category:Hibernian F.C. matches|Scottish Cup Final 2016]]\n[[Category:2016 in Scottish sport|Scottish Cup Final]]\n[[Category:Sports competitions in Glasgow]]\n[[Category:May 2016 sports events in the United Kingdom|Scottish Cup Final]]\n[[Category:2010s in Glasgow]]\n", "text_old": "{{Use dmy dates|date=May 2016}}\n{{Infobox football match\n| title              = 2016 Scottish Cup Final\n| image              = 2016 Scottish Cup Final.jpg\n| image_size         = 200\n| caption            = Official programme cover\n| event              = [[2015\u201316 Scottish Cup]]\n| team1              = [[Rangers F.C.|Rangers]]\n| team1score         = 2\n| team2              = [[Hibernian F.C.|Hibernian]]\n| team2score         = 3\n| date               = 21 May 2016\n| stadium            = [[Hampden Park]]\n| city               = [[Glasgow]]\n| man_of_the_match1a = [[Anthony Stokes]] (Hibernian)\n| referee            = [[Steven McLean (referee)|Steven McLean]]\n| attendance         = 50,701\n| previous           = [[2015 Scottish Cup Final|2015]]\n| next               = [[2017 Scottish Cup Final|2017]]\n}}\nThe '''2016 Scottish Cup Final''' was the 131st final of the [[Scottish Cup]] and the final of the [[2015\u201316 Scottish Cup]], the most prestigious knockout [[association football|football]] competition in Scotland. The match took place at [[Hampden Park]] on 21 May 2016 and was contested by [[Scottish Championship]] teams [[Rangers F.C.|Rangers]] and [[Hibernian F.C.|Hibernian]].<ref name=rangers>{{cite web|url=https://www.bbc.co.uk/sport/football/36008631 |title=Scottish Cup semi-final: Rangers 2\u20132 Celtic (5\u20134 pens) |publisher=BBC Sport |date=17 April 2016 |accessdate=17 April 2016}}</ref> It was the first final to be contested by two teams from outside the top tier of the [[Scottish football league system]].<ref name=rangers /> Hibernian ended a run of 114 years from last winning the competition, beating Rangers 3-2 with a stoppage time goal from [[captain (association football)|club captain]] [[David Gray (footballer, born 1988)|David Gray]].<ref>{{cite news|url=https://www.bbc.co.uk/sport/football/36292302|title=Scottish Cup final: Rangers 2\u20133 Hibernian |publisher=BBC Sport |date=21 May 2016 |accessdate=21 May 2016}}</ref>\n\nThe winners, Hibernian, entered the second qualifying round of the [[2016\u201317 UEFA Europa League]].<ref>{{cite web|author=UEFA Europa League |url=http://www.uefa.com/uefaeuropaleague/season=2017/accesslist/index.html |title=2016/17 UEFA Europa League access list  |publisher=UEFA |date= |accessdate=17 April 2016}}</ref>\n\n== Route to the final ==\n===Hibernian===\nHibernian started the Scottish Cup in the fourth round as one of the top four placed teams in the [[2014\u201315 Scottish Championship]]. They were drawn away at fellow Championship team [[Raith Rovers F.C.|Raith Rovers]]. At [[Stark's Park]], Hibernian won 2\u20130 with goals from [[Darren McGregor]] and [[Dominique Malonga]].<ref name=rai>{{cite web|url=https://www.bbc.co.uk/sport/football/35211876 |title=Raith Rovers 0\u20132 Hibernian |publisher=BBC Sport |date=9 January 2016 |accessdate=17 April 2016}}</ref> In the fifth round, they were drawn away against their [[Edinburgh derby]] rivals and [[Scottish Premiership|Premiership]] club, [[Heart of Midlothian F.C.|Heart of Midlothian]]. Following a 2\u20132 draw at [[Tynecastle Stadium]], Hibernian won the replay at their [[Easter Road]] 1\u20130 via a [[Jason Cummings]] goal.<ref name=hom>{{cite web|url=https://www.bbc.co.uk/sport/football/35535920 |title=Hibernian 1\u20130 Heart of Midlothian |publisher=BBC Sport |date=16 February 2016 |accessdate=17 April 2016}}</ref> In the quarter finals they were drawn at home against the Scottish Cup holders, Premiership side [[Inverness Caledonian Thistle F.C.|Inverness Caledonian Thistle]]. Following a 1\u20131 draw, Hibernian won the replay at [[Caledonian Stadium]] 2\u20131 due to two goals from [[Anthony Stokes]].<ref name=ict>{{cite web|url=https://www.bbc.co.uk/sport/football/35760970 |title=Scottish Cup: Inverness CT 1\u20132 Hibernian |publisher=BBC Sport |date=16 March 2016 |accessdate=17 April 2016}}</ref> In the semi-final at neutral Hampden Park, they were drawn against Premiership [[Dundee United F.C.|Dundee United]] and progressed to the final after winning 4\u20132 in a [[penalty shoot out]].<ref name=duu>{{cite web|url=https://www.bbc.co.uk/sport/football/36003988 |title=Scottish Cup semi-final: Hibernian 0\u20130 Dundee United (Hibs win 4\u20132 on penalties) |publisher=BBC Sport |date=16 April 2016 |accessdate=17 April 2016}}</ref>\n\n{| class=\"wikitable\" style=\"text-align:left;margin-left:1em;float:right\"\n|-\n!width=125|Round\n!width=110|Opposition\n!width=110|Location\n!width=80|Score\n|-\n!colspan=4|Rangers\n|-\n | [[2015\u201316 Scottish Cup#Fourth round|Fourth round]]\n | [[Cowdenbeath F.C.|Cowdenbeath]]\n | [[Ibrox Stadium|Ibrox]]\n | align=center|5\u20131<ref name=cow />\n|-\n | [[2015\u201316 Scottish Cup#Fifth round|Fifth round]]\n | rowspan=2|[[Kilmarnock F.C.|Kilmarnock]]\n | [[Ibrox Stadium|Ibrox]]\n | align=center|0\u20130<ref name=kil />\n|-\n | [[2015\u201316 Scottish Cup#Replays 5|Fifth round replay]]\n | [[Rugby Park]]\n | align=center|2\u20131<ref name=cow />\n|-\n | [[2015\u201316 Scottish Cup#Quarter-finals|Quarter-final]]\n | [[Dundee F.C.|Dundee]]\n | [[Ibrox Stadium|Ibrox]]\n | align=center|4\u20130<ref name=dun />\n|-\n | [[2015\u201316 Scottish Cup#Semi-finals|Semi-final]]\n | [[Celtic F.C.|Celtic]]\n | [[Hampden Park]]\n | align=center|2\u20132 ([[Extra time|a.e.t.]])<br>(5\u20134 [[Penalty shootout (association football)|pen.]])<ref name=rangers />\n|-\n !colspan=4|Hibernian\n|-\n | [[2015\u201316 Scottish Cup#Fourth round|Fourth round]]\n | [[Raith Rovers F.C.|Raith Rovers]]\n | [[Stark's Park]]\n | align=center|2\u20130<ref name=rai />\n|-\n | [[2015\u201316 Scottish Cup#Fifth round|Fifth round]]\n | rowspan=2|[[Heart of Midlothian F.C.|Hearts]]\n | [[Tynecastle Stadium|Tynecastle]]\n | align=center|2\u20132<ref name=hom />\n|-\n | [[2015\u201316 Scottish Cup#Replays 5|Fifth round replay]]\n | [[Easter Road]]\n | align=center|1\u20130<ref name=hom />\n|-\n | [[2015\u201316 Scottish Cup#Quarter-finals|Quarter-final]]\n | rowspan=2|[[Inverness Caledonian Thistle F.C.|Inverness Caledonian Thistle]]\n | [[Easter Road]]\n | align=center|1\u20131<ref name=ict />\n|-\n | [[2015\u201316 Scottish Cup#Replays 6|Quarter-final replay]]\n | [[Caledonian Stadium]]\n | align=center|2\u20131<ref name=ict />\n|-\n | [[2015\u201316 Scottish Cup#Semi-finals|Semi-final]]\n | [[Dundee United F.C.|Dundee United]]\n | [[Hampden Park]]\n | align=center|0\u20130 ([[Extra time|a.e.t.]])<br>(4\u20132 [[Penalty shootout (association football)|pen.]])<ref name=duu />\n|}\n\n===Rangers===\nRangers also started the Scottish Cup in the fourth round as one of the top four placed teams in the previous years Scottish Championship. In the fourth round they were drawn against [[Scottish League One]] team [[Cowdenbeath F.C.|Cowdenbeath]] at home. At their [[Ibrox Stadium]], Rangers won 5\u20131 with goals from [[Lee Wallace]], [[Barrie McKay]] and a [[hat-trick]] from [[Martyn Waghorn]].<ref name=cow>{{cite web|url=https://www.bbc.co.uk/sport/football/35216463 |title=Scottish Cup fourth round: Rangers 5\u20131 Cowdenbeath |publisher=BBC Sport |date=10 January 2016 |accessdate=17 April 2016}}</ref> In the next round they were drawn with Premiership team [[Kilmarnock F.C.|Kilmarnock]]. After a 0\u20130 draw at Ibrox Stadium, Rangers won 2\u20131 in the replay at [[Rugby Park]] with goals from Waghorn and [[Nicky Clark]].<ref name=kil>{{cite web|url=https://www.bbc.co.uk/sport/football/35535921 |title=Scottish Cup: Kilmarnock 1\u20132 Rangers |publisher=BBC Sport |date=16 February 2016 |accessdate=17 April 2016}}</ref> In the quarter finals, Rangers were drawn at home against Premiership [[Dundee F.C.|Dundee]], which they won 4\u20130 with goals from [[Harry Forrester (footballer)|Harry Forrester]], [[Jason Holt]], [[Andy Halliday]] and Wallace.<ref name=dun>{{cite web|url=https://www.bbc.co.uk/sport/football/35675919 |title=Scottish Cup: Rangers 4\u20130 Dundee |publisher=BBC Sport |date=5 March 2016 |accessdate=17 April 2016}}</ref> In the semi-finals, Rangers were drawn against their [[Old Firm]] rivals [[Celtic F.C.|Celtic]] in only their second derby since 2015.  Rangers progressed to the final winning 5\u20134 on penalties.<ref name=rangers /> Rangers entered the final as Scottish Championship league champions and [[Scottish Challenge Cup]] winners.<ref>{{cite web|last=Newport |first=Andy |url=http://www.belfasttelegraph.co.uk/sport/football/scottish/rangers/rangers-have-a-double-reason-to-celebrate-34615149.html |title=Rangers have a double reason to celebrate |publisher=Belfast Telegraph |date= |accessdate=17 April 2016}}</ref>\n\n==Pre-match==\nThis was Hibernian's 1st victory in the [[Scottish Cup Final]] in 114 years, having previously won two Scottish Cups (in [[1887 Scottish Cup Final|1887]] and [[1902 Scottish Cup Final|1902]]) and lost in ten finals since their last victory. The 2016 final marked their third appearance in the final in the space of five years, having lost to [[Heart of Midlothian F.C.|Hearts]] in [[2012 Scottish Cup Final|2012]] and [[Celtic F.C.|Celtic]] in [[2013 Scottish Cup Final|2013]]. Rangers appeared in the Scottish Cup final after winning the competition 33 times. The most recent appearance and victory for the club was in [[2009 Scottish Cup Final|2009]], when they defeated [[Falkirk F.C.|Falkirk]] 1\u20130. This was the first meeting of the clubs in the Scottish Cup since [[2007\u201308 Scottish Cup|2008]], when Rangers won 1\u20130 at [[Ibrox Stadium|Ibrox]] in a replay after a goalless draw at [[Easter Road]]. Hibernian and Rangers had previously met in one Scottish Cup Final, in [[1979 Scottish Cup Final|1979]]. Rangers won the cup that year by winning a second replay by 3\u20132, after the first two matches both finished goalless.<ref>{{cite web |url=http://www.rsssf.com/tabless/scotcuphistfull.html#79 |title=1978/79 |work=RSSSF |date= |accessdate=21 April 2016}}</ref>\n\n==Match==\n===Details===\n{{football box |\n |date = 21 May 2016\n |time = 15:00\n |team1 = [[Rangers F.C.|Rangers]]\n |score = 2\u20133\n |report = [https://www.bbc.com/sport/football/36292302 Report]\n |team2 = [[Hibernian F.C.|Hibernian]]\n |goals1 = [[Kenny Miller|Miller]] {{goal|27}}<br>[[Andy Halliday|Halliday]] {{goal|64}}\n |goals2 = [[Anthony Stokes|Stokes]] {{goal|3||80}}<br>[[David Gray (footballer, born 1988)|Gray]] {{goal|90+2}}\n |stadium = [[Hampden Park]], [[Glasgow]]\n |attendance = 50,701\n |referee = [[Steven McLean (referee)|Steven McLean]]\n}}\n\n{| width=92% |\n|{{Football kit\n|pattern_la=_whiteshoulders\n|pattern_b=_whiteshoulders\n|pattern_ra=_whiteshoulders\n|pattern_sh=_blue stripes\n|pattern_so=_redtop\n|leftarm=0000FF\n|body=0000FF\n|rightarm=0000FF\n|shorts=FFFFFF\n|socks=000000\n| title           = Rangers}}\n|{{Football kit\n| pattern_la = _thinborderonwhite\n| pattern_b  = _whitecollarplain\n| pattern_ra = _thinborderonwhite\n| pattern_sh =\n| pattern_so =\n| leftarm      = 003300\n| body         = 003300\n| rightarm     = 003300\n| shorts       = FFFFFF\n| socks        = FFFFFF\n| title           = Hibernian}}\n|}\n\n{| style=\"width:100%;\"\n|-\n|  style=\"vertical-align:top; width:50%;\"|\n{| style=\"font-size: 90%\" cellspacing=\"0\" cellpadding=\"0\"\n|-\n!width=\"25\"| !!width=\"25\"|\n|-\n|GK ||'''25''' || {{flagicon|ENG}} [[Wes Foderingham]]\n|-\n|DF ||'''2''' || {{flagicon|ENG}} [[James Tavernier]] || {{yel|56}}\n|-\n|DF ||'''4''' || {{flagicon|IRL}} [[Rob Kiernan]]\n|-\n|DF ||'''27''' || {{flagicon|SCO}} [[Danny Wilson (footballer, born 1991)|Danny Wilson]]\n|-\n|DF ||'''5''' || {{flagicon|SCO}} [[Lee Wallace]]\n|-\n|MF ||'''8''' || {{flagicon|USA}} [[Gedion Zelalem]] || || {{suboff|63}}\n|-\n|MF ||'''16''' || {{flagicon|SCO}} [[Andy Halliday]]\n|-\n|MF ||'''23''' || {{flagicon|SCO}} [[Jason Holt]]\n|-\n|MF ||'''19''' || {{flagicon|SCO}} [[Barrie McKay]]\n|-\n|FW ||'''33''' || {{flagicon|ENG}} [[Martyn Waghorn]] || || {{suboff|75}}\n|-\n|FW ||'''9''' || {{flagicon|SCO}} [[Kenny Miller]]\n|-\n|colspan=4|'''Substitutes:'''\n|-\n|GK ||'''1''' || {{flagicon|SCO}} [[Cammy Bell]]\n|-\n|MF ||'''7''' || {{flagicon|ENG}} [[Nicky Law (footballer, born 1988)|Nicky Law]]\n|-\n|MF ||'''14''' || {{flagicon|SCO}} [[Nicky Clark]] || || {{subon|75}}\n|-\n|MF ||'''22''' || {{flagicon|NIR}} [[Dean Shiels]] || || {{subon|63}}\n|-\n|MF ||'''62''' || {{flagicon|SCO}} [[Liam Burt]]\n|-\n\n|colspan=4|'''Manager:'''\n|-\n|colspan=\"4\"|{{flagicon|ENG}} [[Mark Warburton]]\n|}\n|valign=\"top\"|\n|  style=\"vertical-align:top; width:50%;\"|\n{| cellspacing=\"0\" cellpadding=\"0\" style=\"font-size:90%; margin:auto;\"\n|-\n!width=\"25\"| !!width=\"25\"|\n|-\n|GK ||'''25''' || {{flagicon|IRL}} [[Conrad Logan]]\n|-\n|DF ||'''2''' || {{flagicon|SCO}} [[David Gray (footballer, born 1988)|David Gray]]\n|-\n|DF ||'''24''' || {{flagicon|SCO}} [[Darren McGregor]]\n|-\n|DF ||'''4''' || {{flagicon|SCO}} [[Paul Hanlon]] || || {{suboff|83}}\n|-\n|DF ||'''5''' || {{flagicon|ENG}} [[Liam Fontaine]] || || {{suboff|70}}\n|-\n|DF ||'''16''' || {{flagicon|SCO}} [[Lewis Stevenson (Scottish footballer)|Lewis Stevenson]]\n|-\n|MF ||'''8''' || {{flagicon|SCO}} [[Fraser Fyvie]] || {{yel|59}}\n|-\n|MF ||'''10''' || {{flagicon|SCO}} [[Dylan McGeouch]]\n|-\n|MF ||'''18''' || {{flagicon|SCO}} [[John McGinn]]\n|-\n|FW ||'''28''' || {{flagicon|IRL}} [[Anthony Stokes]]\n|-\n|FW ||'''35''' || {{flagicon|SCO}} [[Jason Cummings]] || || {{suboff|65}}\n|-\n|colspan=4|'''Substitutes:'''\n|-\n|GK ||'''1''' || {{flagicon|ENG}} [[Mark Oxley]]\n|-\n|MF ||'''3''' || {{flagicon|SCO}} [[Liam Henderson (footballer, born 1996)|Liam Henderson]] || || {{subon|70}}\n|-\n|MF ||'''6''' || {{flagicon|ENG}} [[Marvin Bartley]]\n|-\n|MF ||'''17''' || {{flagicon|AUS}} [[Martin Boyle]]\n|-\n|FW ||'''19''' || {{flagicon|SCO}} [[James Keatings]] || || {{subon|65}}\n|-\n|DF ||'''27''' || {{flagicon|NOR}} [[Niklas Gunnarsson]] || || {{subon|83}}\n|-\n|FW ||'''29''' || {{flagicon|ENG}} [[Chris Dagnall]]\n|-\n|colspan=4|'''Manager:'''\n|-\n|colspan=\"4\"|{{flagicon|ENG}} [[Alan Stubbs]]\n|}\n|}\n\n'''Match rules'''\n* 90 minutes\n* 30 minutes of extra time if necessary\n* Penalty shoot-out if scores still level\n* Seven named substitutes\n* Maximum of three substitutions\n\n==Post-match==\nAt the end of the match, thousands of Hibernian fans spilled out onto the pitch and were met by groups of Rangers fans leading to fights occurring.<ref>{{Cite web|url=https://www.theguardian.com/football/2016/may/21/rangers-hibernian-scottish-cup-final-match-report|title= Hibernian and David Gray stun Rangers to make Scottish Cup history|date=21 May 2016|work=Guardian|accessdate=24 May 2016}}</ref> Rangers claimed that some of their players and staff had been assaulted by the Hibernian fans as they tried to leave the pitch, however no evidence was shown to suggest this was the case. <ref>{{Cite web|url=https://www.telegraph.co.uk/football/2016/05/21/fights-on-pitch-mar-hibernians-scottish-cup-victory-over-rangers/|title= Rangers 2 Hibernian 3: Post-match violence mars Hibs' astonishing last-gasp victory|date=21 May 2016|work=Daily Telegraph|accessdate=24 May 2016}}</ref> The Rangers team received their runners-up medals in the dressing room. The [[Scottish Football Association|SFA]] conducted a full investigation into the crowd trouble.<ref>{{Cite web|url=https://www.bbc.com/news/uk-scotland-glasgow-west-36350220|title= Scottish Cup final: Disorder after Hibs win 'appalling'|date=21 May 2016|work=BBC Sport|accessdate=24 May 2016}}</ref> The report was published in August and found that neither club was to blame but that the invasion was caused by the Hibs supporters' exuberance at winning the cup. It was pointed out that Rangers supporters had let off fireworks and sung sectarian songs during the match. The report suggested the possibility of making pitch invasions illegal as they are in England.<ref>{{cite news|url=https://www.bbc.co.uk/news/uk-scotland-scotland-politics-36991311|title=Scottish Cup Final report: Consider making pitch invasions illegal - BBC News|date=5 August 2016|work=[[BBC Online]]|accessdate=28 October 2016}}</ref><ref>{{cite web|url=http://www.scottishfa.co.uk/resources/documents/Documents/ScottishCupFinal2016Report/Scottish%20Cup%20Final%202016%20Commission%20of%20Enquiry%20-%20Report%20of%20SP%20Bowen.pdf|title=Scottish Cup Final 2016 Commission of Enquiry - Report of SP Bowen|accessdate=28 October 2016|archive-url=https://web.archive.org/web/20161029113409/http://www.scottishfa.co.uk/resources/documents/Documents/ScottishCupFinal2016Report/Scottish%20Cup%20Final%202016%20Commission%20of%20Enquiry%20-%20Report%20of%20SP%20Bowen.pdf|archive-date=29 October 2016|url-status=dead|df=dmy-all}}</ref> The aftermath of the final is also notable for the five-minute rendition by Hibs' fans, having returned to the stands, of the club's  anthem, the [[The Proclaimers|Proclaimers']] \"Sunshine on Leith\".<ref>{{Cite web|url=https://www.tifofootball.com/features/how-hibernians-sunshine-on-leith-became-an-anthem-for-all-of-football |title= How Hibernian\u2019s Sunshine On Leith became an anthem for all of football\n |date=23 March 2018 |work= Tifo | author= Stephen Tudor | accessdate=23 April 2019}}</ref>\n\n== References ==\n{{reflist|30em}}\n\n{{Scottish Cup seasons}}\n{{2015\u201316 in Scottish football}}\n{{Hibernian F.C. matches}}\n{{Rangers F.C. matches}}\n\n[[Category:Scottish Cup Finals]]\n[[Category:Rangers F.C. matches|Scottish Cup Final 2016]]\n[[Category:Hibernian F.C. matches|Scottish Cup Final 2016]]\n[[Category:2016 in Scottish sport|Scottish Cup Final]]\n[[Category:Sports competitions in Glasgow]]\n[[Category:May 2016 sports events in the United Kingdom|Scottish Cup Final]]\n[[Category:2010s in Glasgow]]\n", "name_user": "Hammersfan", "label": "safe", "comment": "\u2192\u200ePost-match", "url_page": "//en.wikipedia.org/wiki/2016_Scottish_Cup_Final"}
{"title_page": "Tom Gr\u00f6nberg", "text_new": "[[File:Tom Gr\u00f6nberg (01119022).jpg|thumb|Tom Gr\u00f6nberg (2001)]]\n'''Tom Carl Ernst Gr\u00f6nberg''' (born 8 March 1941 [[Helsinki]]<ref name=\"uvf\"/>)is a Finnish diplomat and Master of Law (1971). He has been Ambassador to [[Nairobi]] and [[Addis Ababa]] 1983\u20131987, Deputy Director General of the Legal Department of the [[Ministry for Foreign Affairs (Finland)|Ministry for Foreign Affairs]] 1987<ref>Facta 2001, T\u00e4ydennysosa 1990, WSOY 1990, s. 262</ref>\u20131990 and Head of Department 1990\u20131994. He was an Ambassador to the [[Council of Europe]] in 1994<ref>WSOY Iso Tietosanakirja 3. osa, s. 93, WSOY 1997</ref>\u20131998 and in [[Vienna]], [[Ljubljana]] and [[Bratislava]] 1998\u20132005.<ref name=\"uvf\">[http://uppslagsverket.fi/sv/sok/view-103684-GroenbergTom Tom Gr\u00f6nberg, Uppslagsverket.fi] viitattu 9.9.2016 {{in lang|sv}}</ref>\n\n== References ==\n{{reflist}}\n\n{{DEFAULTSORT:Gronberg, Tom}}\n[[Category:Ambassadors of Finland to Kenya]]\n[[Category:Ambassadors of Finland to Ethiopia]]\n[[Category:Ambassadors of Finland to Austria]]\n[[Category:Ambassadors of Finland to Slovakia]]\n[[Category:Ambassadors of Finland to Slovenia]]\n[[Category:Finnish lawyers]]\n[[Category:1941 births]]\n[[Category:People from Helsinki]]\n[[Category:Living people]]\n[[Category:Permanent Representatives of Finland to the United Nations]]\n[[Category:Permanent Representatives of Finland to the European Union]]\n", "text_old": "[[File:Tom Gr\u00f6nberg (01119022).jpg|thumb|Tom Gr\u00f6nberg (2001)]]\n'''Tom Carl Ernst Gr\u00f6nberg''' (born 8 March 1941 [[Helsinki]]<ref name=\"uvf\"/>)is a Finnish diplomat and Master of Law (1971). He has been Ambassador to [[Nairobi]] and [[Addis Ababa]] 1983-1987, Deputy Director General of the Legal Department of the [[Ministry for Foreign Affairs (Finland)|Ministry for Foreign Affairs]] 1987<ref>Facta 2001, T\u00e4ydennysosa 1990, WSOY 1990, s. 262</ref>\u20131990 and Head of Department 1990-1994. He was an Ambassador to the [[Council of Europe]] in 1994<ref>WSOY Iso Tietosanakirja 3. osa, s. 93, WSOY 1997</ref>\u20131998 and in [[Vienna]], [[Ljubljana]] and [[Bratislava]] 1998\u20132005.<ref name=\"uvf\">[http://uppslagsverket.fi/sv/sok/view-103684-GroenbergTom Tom Gr\u00f6nberg, Uppslagsverket.fi] viitattu 9.9.2016 {{in lang|sv}}</ref>\n\n== References ==\n{{reflist}}\n\n{{DEFAULTSORT:Gronberg, Tom}}\n[[Category:Ambassadors of Finland to Kenya]]\n[[Category:Ambassadors of Finland to Ethiopia]]\n[[Category:Ambassadors of Finland to Austria]]\n[[Category:Ambassadors of Finland to Slovakia]]\n[[Category:Ambassadors of Finland to Slovenia]]\n[[Category:Finnish lawyers]]\n[[Category:1941 births]]\n[[Category:People from Helsinki]]\n[[Category:Living people]]\n[[Category:Permanent Representatives of Finland to the United Nations]]\n[[Category:Permanent Representatives of Finland to the European Union]]\n", "name_user": "Majavah", "label": "safe", "comment": "\u2192\u200etop:clean up,typo(s) fixed: 1983-1987 \u2192 1983\u20131987 (2)", "url_page": "//en.wikipedia.org/wiki/Tom_Gr%C3%B6nberg"}
